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EDITORIAL

Sailing ahead
Joyce T.W. Cheung (Meds 2013)

A

s the academi c year comes to a close for many of us. we are
anticipating a fresh and exc iting chapter of our li ves. I wo uld
like to congratulate the 20 13 cl ass and use thi s platform to th ank
them fo r thei r contributions to the UWOMJ throughout the years. Personally. it has been a pl easure to be a part of the UWOMJ team and the
quality of the contributions has never ceased to amaze me.

All in all , we have prepared an exci ting i ue that covers complex
tertiary care topics and also important prim ary care and preventati ve
hea lth issues related to genitourinary med icine. Congratul ati ons to our
contrib uto rs and rev iewers for a fa ntastic year, and a big th ank yo u to
our readers for your continued support'

Our latest issue featu res the incredi ble genitourinary system and development in this fi eld . It is diffic ult to thin k abo ut th e genitourin ary
system and not have yo ur curi osity piqued by the fascinating topic of
organ transpl antati on. Within the last century. the concept of all ograft
transpl antation has evo lved fro m a procedure that was doomed to eventually fail to a comm on reality. due to advances in surgical technique and
immunosuppressive med ication. Our feature article by Alex Ji ang outlines the latest in do uble-organ transpl antati on of the pancreas-ki dney,
and its therapeutic role fo r th ose suffering from di abetes and end-stage
renal disease. Technological advancements have all owed fo r less in vasive methods of performing surgery. and Laura Callan and Na ncy Chen
outline the fie ld of surgical robotics and give us the latest on research
initi ated here at Western Un ive rsity.
Behind the glamorous fa<;ade, the topi c of organ transpl antation is
as complex as they come. Controversial topics range from ethical problems surro unding candidate se lecti on. to the surgical skill requi red in
perform ing the transplantation, to medica l care afte rwa rds to reduce the
ri sk of organ rejecti on. To start. organs are still an extremely carce resource. so how do we decide on who gets to unde rgo thi s li fe-changing
procedure? Kyle Luong writes about the process of kidney all ocation
and the complex ities of choosing an appropriate candi date. The un predictabl e nature of having a suitable donor organ has led to the business
of transplant touri sm. whi ch is introduced to us in thi s issue by Saad
Ahmed. For those that are left on th e waiting list, long-term hemod ialysis is a life-sustaining treatment. Justine Denomme and Wendy Cui outline the barri ers to access ing hemod ialysis, from its introducti on to the
current state of the system. Our featured clini cian. Dr. Fa isal Rehman. is
no stranger to the world of renal di sease and its treatment. In our interview with Dr. Rehm an. he speaks about hi s vision for the future of renal
medicine and recall s a case that reminded him that despite our advances,
we still have so much more to learn .
We take a step back from the compl ex world of transpl antati on and
march into the front line of medi cine. In the world of primary care
medicine, preventati ve health and prostate cancer screening has become
a controversial iss ue over the years. Our editors update us on the topics
of the role of prostate-specific anti gen and the di gital rectal examination
in prostate cancer screening. From the simple urinary tract infection to
life-threatening urosepsis, Anthony Chow and Elaine Tang teach us how
to approach feve r and incontinence in the emergency department.
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FEATURE ARTICLE

Simultaneous pancreas-kidney transplantation: the
role in the treatment of type 1 diabetes and endstage renal disease
Alex Jiang (Meds 2015), BHSc
Faculty Reviewer: Dr. Patrick Luke, MD , FRCSC (Division of Urology, Department of Surgery)
BACKG RO UN D
ype I diabetes mellitu (OM) i one of the most comm on chronic
di seases of childhood caused by in s ~! in defic iency secondary to
autoi mmune destructiOn of pancreati C beta-ce ll s. The condttt on
affects approx imately 1.4 million indi viduals in United States with an
annual incidence of 17 cases per 100000 children. 1 Unmanaged. it can
lead to severe long-tenn compl icati ons. The se include mi crova cular
events. such as retinopath y. neuropath y. and nephropath y. and macrovascular diseases in vo lvi ng cerebrovascu lar. coronary or periph eral vascul ar sy stemsn These complicati ons are large ly attributed to hyperglycemi a resulting from poor insulin secretion . Consequently. th e mortality
rate for type I OM is hi gh- 13% after 20 years of di sease'

T

One of th e most significati on complicati ons of type I OM is endstage renal di sease (ES RD).' It initi ally manifests as microalbuminuri a
w ith subsequent progre ssion to proteinuria. Without intervention. 80%
of th ese ca es lead to nephropath y and ultimately. ESRD (glomeru lar filtrati on rate < 15 mL/min/ 1.73 m1) . Eligibl e patients w ith ESRD require
dialysis or renal transplantati on for long-term management."
The Di abetes Control and Complicati on T ri al ( DCCT) demonstrated
that ti ght glycemic control. achieved through intensive insulin th erapy.
slows the progression and red uces th e ri sk of developing mi cro- and
macro-vascular complicati ons. 7 Despite use of insulin pumps and intensive insul in th erapy. no exogenous deli very of insulin has been ab le to
sustain normogly cemia as effecti ve ly as a fun cti onal pancreas. A s such.
all oge neic pancreas transplantati on was developed to ac hi eve norm aglycemi a and insulin independeru;e. The combinati on of pancreas and
kidney transplantati on can render a pati ent free of both insulin and dialysis with prevention of furth er diabetic co mp lica ti ons, and occasional
reversal of estab li shed di sease.'

PANCREAS TRA SPLA TATIO

HI STORY

SELECT ION PROCESS
T he SPK procedure is usual!) reserved for a pati ent with type I OM as
confirm ed by IO\\ or absent leve l of C-peptide. 13 Candidates may also
have signi fican t neph ropath) or E RD. along with complications such
as hypogl ycem ic unawareness. recurrent hospitali zati on from diabetic
ketoacidosis. progress ive retin opathy. enteropathy and neuropathy."

SU RG ICALP ROCED RE
The techniques used for SPK transplantati on are diverse and instituti ondependent. Most tran spl an t centers use the intraperitoneal approach for
graft placement. The pancreas is transplanted to a heterotopi c location.
usually the ri ght iliac fossa. \\ hil e the kidn ey is tran splanted to the contralatera l iliac fo sa. T hi s approach results in fewer peripancreati c fluid
co llec ti ons and wound compli cat ion s. A n alternati ve approach involves
extraperitoneal and ipsilateral placement of both graft s. 15
A rteri al anastomo is ma) be perfonned by conjoining th e donor superior mesenteric artef)' and splenic artery to a Y graft of the recipient
ex tern al or comm on ili ac artery. T he donor portal vei n is anastomosed
to th e extern al ili ac vei n i f s) stemic drainage is pro vided. An alternative
approach is anastomosis of donor porta l ve in to superi or mesenteric vein
if portal venou s drainage is ava il able. 16 A lthough thi s was performed to
red uce li pid dysrcgu lati on and rej ecti on rates. contemporaty studies
have shown vel)' littl e di!Terences in overall long-term outcome between systemic and portal drainages. 17

OUTCOMES

The first pancreas transpl antati on (PT) was perfo rm ed in 1966 by William K elly and Ri chard Lill ehei at th e Uni versity of Minnesota in conjunction w ith a kidn ey tran plant to treat a di abeti c uremic pati ent.'> Earl y
procedures were as ociated with significant morbidity and mortality and
performed in low numbers in very elect patients. With the advent of
cyc losporine and improvements in surgical techniques, one year graft
survi val rates exceeded 70% in 1980s. 1"To date. more than 32000 cases
ha ve been perform ed world wide w ith ever improv in g outcomes. 11
Currently, th ere are three meth ods of solid organ pancreas transpl antati on. The maj ori ty (83%) of procedures are perform ed in th e context
of simultaneous pancreas-kidn ey (SPK) transplantati on where th e pancreas is tran spl anted at th e same tim e as th e k idney. T he second meth od
is pancreas aft er kidney (PA K) transpl antati on ( 12%) where a pancreas
is transplanted to a pati ent who prev iously received k idney transplanta-

4

tion . The third meth od is pancreas transpl ant alone (PTA) (5%). which
in vo lves transpl antation of a solitary pancreas to a diabetic patient with
norm al renal fun cti on. T hi s is perfonned to counteract life-threatening
hypogl ycem ic unawareness or rapidl y progres ive diabeti c complicati on s refractof) to intensive insulin th erapy. 11

Survival
It is believed th at th e PK procedure prolongs patient survival beyond
th e urvival advantage associated with renal transplantation alone. The
5- and I 0-ycar pati ent surviva l rates for PK transplantation is 87% and
70°o. respecti ve ly.wfhi s is significantly better than the surv ival rates for
type I diabeti cs rece iving maintenance dia lysis and who are on transplant wa iting li st. 19 l-l owever, due to inherent biases in li stin g candidates
for transplants. and the differences in donor age between PK and solitary kidn ey (SK) tran spl ant cohorts. the true survival benefit conferred
by th e pancrea is unknown .
Graft surviva l rates are excellent. The pancreati c allograft survival
rate is 86% at one year and 53 % at I 0 years w hile kid ney urvival rate
is >95% at one year and 60% at I 0 years. 1R·211 Th e lower one year graft
survi val rates for the pancreas are secondary to early transplant compli-
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cati on , including thrombo sis. pancreatic fistula. and infection .l'.l"

Quality of Life

Nep hropathy

Pancreas transp lantati on can improve quality of life (QOL) by eliminatmg dmb_etes associated compli cation s, including hy po/hyperglycemi a,
metaboltc derangements. insulin dependence, glucose monitoring and
21
dtetary rest_riction s. . mith et al. co mpared pre- and po st-transplant
<?0~ and tound tgntficant improvement foll ow ing PK tran splantaF-36 Mental omponent Sum mar) sco res were signifi cantly
ti on.
higher 2 years post-tran splant co mpared to pre-tran plant (5 1.8 v .
46.8). Similar results were obtained from the Ph ysica l Component urnmary (PCS) score (48.1 vs. 40.6) n

M ost patients with type I DM and ES RD receive SPK to improve their
rena l function. Fioretto et al. reported that I 0 years of sustained normagly ce mia post-tran splant reversed features of diabetic nephropath y. 2 ~ It
signifi ca ntl y improved g lomeru lar and tubu lar lesions. and reduced the
thickn ess of glomerular basement membrane and mesangia l matrix. A
decrea e in urinary albumin excreti on rate was also ob erved (20 mg/
day vs. I 03 mg/day ) high lighting improvem ent in renal fu nct ion. H o~\ 
ever, improvements in diabetic nephropa th y post-tran splant need to be
balanced w ith nephrotox icity incurred by th e use of immuno uppress i ve
agents such as tacrolimu s and cy closporin e 3 "

Glycemic Control

Retinopathy

T he vast majori ty of patients ach ieve co mpl ete insulin independence
over the hort and long-tem1 following solid-organ pancreas transplant.
In fac t. g lycem ic control is far superi or to th at achi eved by insulin
pu~p or islet-ce ll transplantsn Mora et al. demonstrated th at rec ipi en ts
acht_
eved long-term norm oglyce mic state foll owing SPK transplantN
Dunng the 15 year fo llow -up. HbA I c leve l remained wi thin normal
range w ith no significant difference bet\\een th e first and the Ia t year
of follo~\-up (4.68% vs. 4.76%. p> 0.05) Y Fasting g luco e level al o
remained stab le during the same period (3 .94 vs. 4.38 mmol/ 1, p>0.05)N
However, oral glucose to lerance test (OGTT) demon strated decreased
pancreatic re pon se. indicating certain deteri orati on in th e functional ca pability of the all ograft over th e long-term H Whether thi s is the effec t
of immunosuppressive medications (i .e. tacrolimu s. sirolimus and prednisone) on islet-cell function. insulin res istance. immun e-related chronic
changes. or a co mbinati on th ereof, is unknown.

Diabetic retinopathy (DR) is the most common micro vascu lar com pli ca ti on of diabetes. Several studies have reported conflicting result about
th e effects ofS PK on retinopathy. However. most recent studie s indicate
that SP K , w ith subsequent normali zati o n of blood g lucose leve l. can
improve or norm ali ze retinal lesions3 1Fo ll owi ng SPK transplantation.
14% of non-blind eyes howed improvement. 76% rema ined stable and
only I 0% progressed further 32 A separate study reported an improvement in post-tran splant vi ual ac ui ty in 32% of th e ey es and frequency/
severity of vitreous hemorrh ages in 46% of eyes31It may take up to 4
years before noti ceab le functional improvement in reti nopa thy and acuity may be observed . Pancreas transpl antati on. however. ca nnot reverse
establi shed visual loss.

2

1'ascular
The pancreas transplant doe not reverse establ ished macrovascular di sease in recipients. Instead. it is believed to slow down th e progression
of disease in thi high-risk popu lation. Nevertheless, fi ve years after
tran spl antation. th e prevalence of cerebrovasc ular disease (C VD), coronary heart disease (C HD) and peripheral vascular di ease (PVD) is sti ll
33%. 41% and 41 %, respective ly. Ten year after transp lantation s, the
ri sk increased only lightly to 4 I %. 50% and 50 % , respecti ve lyY Us ing
peripheral th ermography studi e , it is be lieved that microva cu lar perfusion is improved post-pancreas transplan t as a result of better glycemic
control 26

Ne uropathy
Previou s studi es demonstrated a benefit of SPK transp lant for diabetic
polyneuropathy. K enedy et al. analyzed th e effect of pancreas tran plantation on peripheral motor, sensory and autonomi c nerve function based
on indexes of nerve conduction ve loc ity and musc le acti on potentiai Y
After I 2 months of follow-up. they found a ignificant improvement
in motor and sensory indi ces. Thi s i supported by Martinenghi et al. ,
\\ hich demonstrated th at a sustained norm og lyce mic tate can amel iorate nerve fun cti on even if poly neuropathy is advanced 1 8

CONCLUS ION
SPK transplantation is th e most effec ti ve treatm ent for patients " ith type
I DM and ES RD . It add resses renal fai l ure and provides phy iologica l
means of attai ning stab le insulin secreti on. A lthough it in vo l ves major
surgery and is not without ri sks, it nonetheless increases pati en t survival.
enhances QOL and prevent progression of diabetic comp li ca ti ons. A s
such. they should be co nsidered in all eligible patients.
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Pathogenic mechanisms and direction of empirical
studies: a retrospective on membranoproliferative
glomerulonephritis
Alexander Pazionis (Meds 2015) and Denise Darmawikarta (Meds 2016)
Faculty reviewer: Dr. Faisal Rehman , MD , FRCPC, M.Ed (Department of Medicine , Division of Nephrology)

M

embranoproli fe rati ve glomerul onephriti s (MPGN) is an
immune-mediated di sease process, underl ying I 0%-20% of
nephrotic syndrome cases in children and yo ung adults.' The
Ty pe I subtype (C lass ical MPGN) is the most common Hepatiti s C Vi rus (HCV)-as oc iated nephropathy. 2 Still. though all MPGN subtypes
(1,11.111 ) can slow ly progress to end-stage renal di sease (E RDS). 3 the
condi tion is uncomm on enough to acco unt fo r just 2.8% and 3.3% of all
cases in ped iatric dialysis patients and pediatric renal transpl ant recipients. respectively.' This may ex plai n. in part. why studies on the efficacies of va ri ous immunosuppressive agents in thi s conditi on are. on the
whole, relatively limited.
evertheless, the general fi ndings (w ith excepti ons) appear to indicate these agents are either ineffecti ve or min imally effecti ve in MPGN
(depend ing on the subtype). In the current model of evidence-based
medici ne (EBM). it is understandabl e that much of clinical practi ce and
research be guided by empirical findin gs. Nonetheless. when examining the theoretica l pathogenesis of MPGN along with what is kn own
of the mechanisms of action of these age nts. it retros pecti ve ly becomes
clear that some of these agents were unlikely to be effecti ve in the fi rst
place. Thi s is not to say that theoretical understanding should be trusted
without empiri cal veri fica tion. However. in the same way that a clinician
should consider what is kn own about an indi vidual pati ent and order
tests acco rdingly, it behooves the in vestigator to consider what is kn own
about a condition before conducting an empiri cal study.
In this review, we di scuss the underlying pathogeneni c mechani sms
of MPGN and rev iew currentl y availabl e treatm ent. We focus on idiopathic MPGN, as most cases of MPGN in adults have secondary causes
(e.g. cancer. hepatiti s C) and treatment wo uld accordingly target those
underl ying conditi ons.

Ty pe I -Ev idence of act ivati on of th e class ical and alternati ve complement path ways. ex hibiting on imm unohi stoc hemi stry glomerul ar deposits of immunoglobulin (indicating immune complex deposition as a
contri buto r to the di sease process). as we ll as components unique to the
class ical complement cascade (C Iq. C4) in add it ion to those common to
both the classical and altern ati ve path ways (C3 ). 1
Type II - Also known as · Dense Deposit Disease: with conspicuous absence of components unique to th e class ical compliment cascade
(C iq. C4) vis-a-vis abse nce of immun og lobulin depositio n. whil e still
maintaining ev idence of C3 depositi on in the kidney( s). 1 The impli cation is a ' pure· alternati ve path way component and a theoreti cal absence
of an adapti ve immunity contribution.
Ty pe Il l - Less easil y classifi ed and arguably the rarest of the three
commonl y acknow ledged subty pes. It is often considered a vari ation of
Type I. It di spl ays ev ide nce of poss ibl e immune complex depos ition as a
mediator of glomerul ar damage via the observation of immu noglobulin s
on immunohi stochemi stry. but, as mentioned previously. is also hi ghl y
associated with over acti vati on of the terminal path way of the complement cascade.
While th e pathogenesis of MPGN is now becoming clearer, it is interesting to realize that currentl y employed therapeuti c age nts do not
necessaril y target components of the di sease mechani sms.
~9
Binding of
complement
proteins to
microbial cell
surface or
antibody

The class ical path way is part of the arsenal of the adapti ve immune
system's humoral arm .B The alternative path way, on the other hand. is
a part of non-specifi c or ' inn ate' immun ity, and does not require antibodies, like the classical path way does. 8 However. after the cleavage
of CS to CSa and C5b, classical and alternati ve path ways converge to a
common molecul ar sequence.R It is at this stage, the so-called ' terminal'
path way that over-acti vati on seems most hi ghly assoc iated with MPGN
111.39. 10 With thi s in mind, we may classify the subtypes of MPGN as
follows:
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The complement cascade consists of a seri es of proteo lytic steps catalyzed by the products of prev ious steps in the eri es.R Figure I is a
di agrammatic representati on of the complement cascade. which can be
acti vated via more than one pathway: the two most relevant to the di scuss ion being the so-called ·c lassical' and ·alternati ve ' path ways.
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CORTICOSTEROIDS

An important tudy to consider in detai l is a report of th e Internati onal
Study of Kidney Di ease in Children. '' This study showed a stati sti call y
significant decrease in treatment fai lure for children with MPGN I and
Ill. meeting th eir inclusion criteria when treated with predni sone rather
than placebo (p = 0.028). However. results were not stati sticall y significant for chi ldren with MPGN II included in th e study, though it was
underpowered in thi s regard. Th is was corroborated by Donadi o and Offord, 12 whose study also failed to show benefi t in adult MPG N II pati ents
comparing predni sone to place bo. Finall y, thou gh not quite reaching stati stical signifi cance (p = 0.07). there was a trend toward stab le, improved
renal fun cti on considering all participants with MPG I. II and Ill at
130 months of foll ow-up.' ' A 11 eak.n ess of this study is th at it did not
diA'erentiate betwee n MPG I and MPG Ill und er th e assumption th at
MPGN Ill was a subcategory ofM PGN I. Potential differences between
these two groups 11ere eva luated in a retrospective study by Braun et.
al '3 th at showed statisticall y significant differences between a number
of characteri stics between MPG I and MPGN Ill pati ents treated with
pred ni sone at 3 years of follow up. Patie nts with MPGN I, compared
with th ose hav ing MPGN Ill. ~ere found to have more stabl e GF R's,
lower rates of persistent hypocom plimentemia (C3). and lower rate of
persistent hematuria and proteinuria. to name a few.
Thus. with what evidence th ere is. a possibl e theoreti ca l simplification is as follows wi th respect to th e effect iveness of stero ids in MPG
MPGN I - Effecti ve
MPG

Ill - Less Effecti ve

MPGN ll -

ot Effecti ve

The effects of steroids are so categori cally broad th at any ex plan ati on
on a mechani stic bas is of these categories would amount to spec ul at ion.
More simply put, it is diffi cult to identify differences in similar di sease
entities based on responses to a drug with broad effects. Oth er agents
with greater specifi city allow us to better di stinguish such differences
on th e bas is of theoreti cal know ledge. Thi s is illustrated nex t, by th e admittedl y limited number of stud ies perform ed on calcineurin inhibitors.
CALCI EURIN INHIBITORS

Calcineurin med iates the acti vati on of nuclear factor of ac ti va ted t-cells
(NFAT). a transcripti on factor encodin g a number of ge nes including
I L-2 .~ IL-2 is necessary forT-ce ll proliferati on." Other ge ne , such as
C D40L and oth ers req uired forT-ce ll s to be able to acti vate B-ce ll s are
also produced. Bl ocking calcineurin, th erefore, is expected to ha ve a
number of effects on th e adapti ve immune system including decreased
antibody production and dec reased T-ce ll inA amm atory mediator release.
The possibility of using ca lcineurin inhibitors is best illu trated in
two studies. The first, by Bagheri et. al. studied 18 patients with idiopathic MPGN (lMPG ) 15 . They showed th at partial or complete remission of proteinuri a was achieved in 94% (p<O.O I) of patients, and th at
at an ave rage follow-up of I08 weeks. just one of th ose showed remission once treatm ent was di scont inued 11 .A noth er study. by Singh et. al.
similarly sho wed tatisticall y signifi cant reductions in proteinuria in 8
patient with MPGN treated with cyclosporine 16.However, both of th ese
studies fa il ed to di stin gui sh betwee n different subtypes of MPG N. Bagheri et al. made no mention at all of different subtypes, and though
Singh et al. disclosed that 5 of the MPGN pati ents were Type I and 3
were Type II , th e data for all these patients were ultimatel y combined .
The pathoge ne is of MPGN l is directl y linked to th e classical pathway
of compliment ac ti vation. wh ich constitutes part of adaptive immunity
and th erefore is, in th eory. potentially susceptibl e to inhibition by ca l-
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cineurin inhibitors. Thi s cannot be stated with certainty based on the
studies di scussed as they did not di ssociate the effects of calcineunn
inhibitors on ty pe I vs . type II. MPGN II. on th e other hand. IS lmked
to innate immunity, and though there have been incidental case reports
of MPGN II patients respondin g to cyclosporine", long-teml foll_owup studies of small numbers of patients show that calcineurin Inhibitors
have no impact on renal survival in MPGN II patients 17• Long-tenn renal
survi val in MPGN I patients treated with cyc lospo rin e should be further
in vesti gated.
CONCLUSION/FUTURE DIRECTION

Whil e some ev idence exists th at suggests a role for other treatments,
such as acety l ali cy li c ac id. dipyridamole, cyclophosphamide and
Coum adin (warfarin). in MPG . it is unfortunately of poor quality 1R.
Randomi zed controlled trials should be conducted to study these variou treatment option for MPGN. Given th e ge neral ineffectiveness of
current MPGN treatm ent. it is imperative that future in vestigations on
potenti al th erapeutic agents be conducted on the bas is of known pathoge nic mechani sms.
A promi sing treatment opti on fo r MPG that has been elucidated
by case reports 5-7 is Eculi zu mab . Eculizumab is a monoclonal antibody for C5, a member of the complement cascade that form s part of
th e MAC. Given the path ogenesis of MPGN . th e use of Ecu lizumab
makes intuiti ve sense and thus it is unfortunate that littl e is yet known
about th eir effecti ve ness in the treatment of MPG . Insofar as C5 is
in vo lved in both th e classical and altemative pathways of complement
acti vation. all three subtypes of MPG (w hich. somewhat simplified.
may be characterized by di ffe rential ratios of classical:alternative pathway acti vati on). could theo reticall) be treated with thi s medicati on. Future studies should th erefore investigate the potential for Eculi zumab
in treatin g MPGN. insofar as potentially. all three subtypes of MPGN
could be treated with thi s age nt.
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DIAGNOSTIC REVIEW

Digital rectal examination in prostate cancer
screening
Angela Zhang (Meds 2015), Thomas Fear (Meds 2015) , and Hammood Ahmed (Meds 2015)
Faculty Reviewer: Dr. John Jordan, MD (Department of Family Medicine)

I TROD UCTION
Digital rec tal examination (O RE) ma) be performed in order to identi fy
rectal di sease, prostate cancer. exami ne anal ph incter tone. or to examine female gyneco logica l stru ctu re . Rectal examinati on has been descri bed by conflicting opini ons as both a cause of .. more harm than good ..
and conversely as a .. crucial part of the examinati on [of a pati entr .u
Despi te its man) diagnostic appli cati ons. the test is also uncomfortab le
for some pati en ts. doctors. and medica l students. T hi s arti cle w ill foc us
on th e characteristics of the test in pro tate ca ncer screening. and how
th e chall enges of pati ent resistance and medical student educati on can
be addressed.

ROLE OF DRE I N PROSTATE CANCE R SCREEN ING
What lies at th e center of the ORE debate is its utility for iden ti fy ing
and diagnosing differen t diseases. One applicati on for ORE is for th e
detection of prostate cancer which is the most comm on cancer in men
oth er non-melanoma skin cancers. It was diagnosed in 26.500 Canadians in 20 12, and resulted in 4000 death s3 However the disease is often
indolent. and while one in seven men are diagnosed. only one in 27 men
die from th e disease.' T he va lue of ORE can come into questi on because
studies confl ict as to wheth er screening fo r pro tate cancer can lower
morbidity' oneth eless. because of th e frequency of th e di sease and th e
poss ibili ty detect ing th e disease when it is curabl e many pati ents and
physicians choose to screen.
T he ORE is an inexpensive test th at in vo lves asse sment of pro tate
size. consistency, mob ility. and irregu larit ies in shape. However th e size
alone is not a use ful pred ictor of prostate cancer ri sk and th ere is low
correlati on be tween transrectal ul trasonograph y (TRUS) measured prostate vo lum e and OR E estim ated vo lum e.H A dditi onall y, whi le carcinomas are fe lts as hard irregu lar nod ul es similar indurati ons may also be
cau ed by benign prostati c hypertrophy ( 13PI I) or ca lculi . Thi s means an
examiner mu st ord er further tests when any indurati on is felt, and repea t
th e test regul arl y to detect for any changes or progression 5 · ' Th e exam
also req uires techni ca l skill. Not all examiners can palpate the entire
posteri or surface of th e prostate. T he abi I ity of an exa miner to reach and
examine th e ape x of th e prostate. hal f of th e prostate. three quart er of it,
and th e entire prostate in a recent study was 93.7%. 66.3%. 23 .2% and
3. 2% for th ese respec ti ve components of the prostate gland. 7 Ev idence
for th e importance of techni cal skil l in OR Eal o comes from studi es of
inter-examiner vari ation. One study compared consultant and res ident
urologists who perform ed OREs to determin e if prostates were suspicious for cancer. Th e overall agreement was ex pressed with a kappa tati sti c of 0.22, whi ch suggests only fa ir agreement between examiners.
However, whil e th e kappa stati sti c among residents was 0.25; among
consultants it was 0.63 whi ch suggests a substanti al level of agreement. '
Further research has shown th at more ex peri enced urol ogists tend to as-
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sess th e size of a prostate more accurately. 9 Th ese findings upport th e
idea th at techni ca l skill i important to success full y performing OREs.
One means to address thi s i th rough improved educati on of medical
train ees. a topic addressed later in th is arti cle.
Wh en ORE is used to screen for prostate cancer in men over 50 years
of age. the cancer detecti on rate is 3.2% w ith a pos iti ve predi cti ve value
of2 1%. T he sensiti vity and spec ifi city of DR E are 21 % and 86% respectively. 1" It is also recomm ended that ORE is perform ed in conjunction
1~ ith prostate specific anti gen (PSA) in prostate cancer screening because thi s improves th e overall sensiti vity. Whereas th e prostate cancer
detec tion rate was 3.2% fo r digital rec tal examinati on, it was 4. 6% for
PSA and 5.8% for the 2 meth ods combined. 11 Of note is th at the detec ti on rates of the two tests onl y partially overl ap. and together the two
te ts detect more cases of prostate cancer.
In conclusion. because the disease is relative ly indolent, it is recomm ended th at an in fo rmed dec ision is made by pati ents wheth er or
not to screen fo r prostate cancer. Because the test is technically diffi cult
to per fo rm . steps shoul d be taken to improve th e education of medi cal
tra in ees. I f screen ing is to be perform ed. then regul ar ORE is recommended to be used conjuncti on w ith PSA testing to increases th e rate of
cancer detecti on.

PAT I ENT BA RRI ERS
Some pati ent barr iers to th e acceptance o f OR Es include di scomfort.
embarrassment and men assoc iatin g th e exam w ith homosexuality. Furth erm ore some men arc 1-1orri ed about fee lin g stimul ated and having an
un wanted and uncontrolled ph ysica l response during a ORE. M en may
not seek medica l attenti on th at includes ORE until they' re no longer able
to cope w ith sy mptoms: thi s could be due to both fear of th e procedure
or fear of disco verin g i ll ness. One ~~ ay to improve pati ent acceptance of
OR E i to im prove pati ent educa ti on. A mpl e in fo rm ati on on th e process
and reason for perfo rmin g the procedure should be provided for pati ents.
To be included in th e conver ation coul d be di cussion about past experi ence with ORE. whether positi ve or negati ve. Positi oning can also
be chosen to reduce pati ent embarrassment during th e procedure. The
left lateral position has been show to be th e least embarrass ing w ithout compromi sing th e re ults of th e test. 11 Furthem1ore. many patients
view co lonoscopy drasti call y differently th an OR E. Th e reason is that
co lonoscopy is often perce ived as more technol og ical and hence perceived as more scientifi c. Therefore extra care should be taken by physicians to maintain a professional environment during ORE. Language
used should be chosen carefu l ly. For example, phrases li ke ' examine'
th e prostate rath er than ' fee l ' the prostate make the proce s ound more
cl in ica l and scientifi c, hence more accepted by pati ents w ho are wary of
th e procedure. 13

TEACHING OF THE DRE
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One factor limiting the usefulness of ORE is in ter-examiner vari abi lity,
w hi ch results in inconsistent exam findings. Thi s has promoted studi es
th at examin e how th e digital rec tal exam is taught to med ical stud ents
and res idents. Teaching during medical schoo l has a huge bearin g on
a physician's future kill in performin g ORE, yet se veral aspects limit
what students learn . ORE is often learned through tex tbook reading and
facilitator demonstrati ons. T he three dimensional nature of th e prostate
is di ffic ult to convey in tex tbooks. In demonstrati ons. it is challenging
to teach th e subtl eti es of palpati on because OR E is a very intern al procedure.1 4
One attempt to solve thi s problem uses rectal simul ators whi ch are
currently being deve loped to teach th e OR E. A manneq uin mode ling th e
rectum and prostate i attached to electroni c sensors, so th at when an
examiner palpates the rectu m sensors analyze th e pressure and locati on
of palpation for instructors to assess and give feedback . Beyond use as a
teaching tool. thi s simulator can also detect differences in performance
between examiners and so attempts to quanti fy inter-examiner vari ability in ORE.
Un ive rsity of Ca lifornia Medical Schoo l deve loped a ORE teaching
mode l that include didacti c lectures. practical learning by performing
the procedure on a standardi zed pati ent, and small group sessions led by
fac ulty members. In a study conducted by K apl an et. al. stud ents· comfort level in term s of performin g ORE were comparin g bel\veen group
of students that recei ved ORE trai ning from the new teaching mode l and
students th at didn ' t receive forma l training in performing ORE. Students
who had received the teaching model were more comfortable performing OREs. Examiner comfort and confidence level is crucial to pati ent
comfort and confidence; hence thi s mode l of learnin g through three modalities shou ld be given consideration for more widespread use in th e
teaching of medical students. 15

CONCLUS ION
De pite differences in prostate cancer screening guidelines bel\-veen
vari ous co untri es, the majority of co untri es recomm end a com binati on
approach of serum PSA w ith DRE. 1r' T herefore OR E is still an important
part of undergrad uate and postgrad uate medical curricul a.
Things to keep in mind :
Reassure your pati ent: explain to th em why you' re doing thi s exam
and what to ex pect during the exam.
Use medical term s to describe procedure: examine. palpate, drape,
examination tabl e etc.
Ask th e patient if they have ever had a bad ex peri ence during a
ORE.
Position choice: left lateral po iti on is perceived by pati ents to be
least embarrassing, while ach ievi ng simil ar results as oth er positions. 16
There are limitations to use of ORE in pro tate cancer sc reening. However as a procedure that is low ri sk. fast and office setting proced ure
when used in combin ation with PSA increase cancer detection comparing to PSA alone, th ere is still a place for ORE in medicine and prostate
cancer screening today. There is inter-examiner vari ab ili ty meaning th at
experi ence leve l has an impact on efficacy of thi s test. Therefore ORE
should to be more ri gorou sly taught to new generation s of phys icians
and care should be taking regardin g how OR E is taught. M odifications
should be made to th e teaching of thi s procedure in medical school s.
Traditional learning from texts and demonstrations should be enh anced
by the incorporati on of modem technology like ORE simul ators and
more comprehen sive teaching models to educate future phys icians.
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ale. 45 )ears old. presenting wi th severe sepsis- ru shed in
straight from th e airport. On fu rth er in vest igati on th e pati ent
also has an inA amed incision lateral to th eir upper ri ght abdominal quadrant th at seems infected. T he famil) seems ti ght-lipped
abo ut th e detai ls of th e trip. but on pressing they menti oned a ki dne)
transpl ant done abroad as the rea on.

M

What do) ou do in this situation?
I NTE RNAT IO ALLY:
In 2008 delegates from all around the \\ orl d drafted th e Istanbul Declaration. It expl ici tl y stated th at organ trafficking and comm ercialism
expl oits the poor and should be completely bann ed.' Wh ereas orga n trafficking is done with coercion and usually violence. even organ commerciali sm in volve a certain amount of monetary coe rcion, espec ially sin ce
th ere are power asy mmetri es between someone in a deve loped country
and a desperately poor person in a developing country.' Th ose wh o are
fo rced to sell th eir kidne)S as a result of fi nancial hardships frequently
report th at they are left frai l and sick. w ith th e money di sappearing in
no time. 2 Secondly. multipl e studi es from Canada. th e US, and A ustrali a
have hown that the health outcome of transpl ants tourists are signi fi cantly worse than pati ents who rece ived th eir transpl ants domesti cally
and legitim ately.
T he policy makers at the Istanbul Dec larati on recognized th at organ traffi ckin g and commerciali sm is ultimately dri ven by demand from
peopl e in deve loped co untries who are sufferin g on organ rec ipi ent
waitli sts. To thi s end. th ey reinforced th e importance of policies th at
increase dome ti c organ donati on rates.' some of whi ch have been adopted in Canada. A n exampl e of th ese poli cies being put into prac ti ce is
th e L iv ing Donor Paired Exchange (LOP E) Reg istry, a nati onal registry
for pati ents suffe rin g from chroni c k idn ey di ca e. and th e Li ving Organ
Donor Reimbursement Program ( LO DRP), which has been adopted in
at least 5 prov inces. Th e LO DRP reim burses organ donors for va ri ous
ex penses and tim e lost throughout th e process of donati on and recovery.
Th e LOPE matches transpl ant pati ent who have incompatibl e living
donors w ith each oth er - th e idea being th at one pati ent 's incompatibl e
donor may be compatib le w ith anoth er pati ent, who e li ving donor may
be compatibl e w ith th e fo rm er pati ent. It ha been shown to incn.:asc
organ donati on by up to I 0%.3
Th e Dec larati on has had signifi cant inAuence globall y - especially
in countries form erl y considered to be hotbeds of organ traffi cking and
commercialism, such as Chin a. Paki stan and th e Philippines. Legislati on is now in pl ace to prohibit th e practi ce.'' Countries are also workin g
togeth er to apprehend and charge those w ho continue to participate in
organ traffi cking. For instance. European and Canadian authoriti es in
K osovo recently di smantled an infamous organ traffi cking rin g spread
out across three continents: and a crimin al tri al has begun to sentence
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th e traffi ckers2
DOMEST I CALLY:
In Canada. the Canadi an Society of Transplantation and the Canadian
Society of eph ro logy j ointly released a policy statement on organ traffic king and transpl ant tourism. In th eir preambl e, th e) affirm ed the principl es of th e I tanbul Dec larati on 5 and a physician ·s duty to never deny
care to a pa ti ent. T he main crux of the policy statement is focused on
preventing peopl e fro m undergoi ng transplant touri sm in th e first pl ace.~
T he myri ad pro blems and complications of transplant touri sm should be
coherent!) communi cated to patients- such as th e diffi culty in receiving
in surance coverage for long-term anti-rejecti on medi cati ons due to th e
lack of documentati on and unethical nature of th e transplant• To thi s
end . the Kidney Foundati on of Canada released a set of pamphlets that
warn people about the possible consequences of transplant touri sm (see
http : //www.kidney.ca /docu ment.doc?id- 1239).
T he data from a ingle centre study whi ch looked at 93 transplant
touri sts fro m British Co lumbia. affi rm s the need to r th orough and proper
pre-tran plant counseling. 6 T he tud) fo und that 30% of th e re pondents
had never been referred for a transplant consult, and had thus preempti vely undergone a kidn ey transpl ant. noth er 33% of th e transpl ant
touri ts in th e study had compl eted a transpl ant consult. and after being
waitli sted lo r a transplant sought a commercial transpl ant. T hi s speaks
to a need for a multi-faceted policy. I f 30% of transpl ant touri sts are
pre-empti ve ly rece iving transpl ants without an actual referral after the
development of end-stage renal disease, it speaks to a need for public
campaigns di sco uraging transpl ant touri sm. as well as a need to educate
pati ents before the deve lopment of end-stage renal di sease. Secondly.
oth er pati ents recei ved a referral. but fail ed to foll ow up and were lost to
th e system - hence th e tud y mentions that pati ents must be track ed better. Furtherm ore. considerin g th at th e vast maj ority of tran spl ant tourists
were ethni c minorities.j th e stud y argued th at outreach effot1s must be
made to members of the e communiti es to discourage transplant tour' ~n . A nd for th e 33% of _pati ents wh o had gone abroad to r a transplant
alter bctng put on a wa1tlt sl , th e study advocated for poli cie such as the
Paired Li ving Donor Exchange Registry. Studi es held in centres across
the US and Australia had simi lar findin gs and recomm endation s_7.a.9
N umerous pub lic hea lth problems have been rai sed by a anadi an
~tudy o f transplant touri sts. 10 Th ere have been cases of pati ents presenttn g wtlh mu lttpl e drug-res tslant Escherichia coli, acti ve tuberculosi a
~ve il as oth er viru es ~ nd funga l in fecti ons not typically seen in an a,da.
fh e pre~ence ofmu lttpl e drug resistant bacteri a certainl y poses a domeslt c publtc hea lth conce rn .
LEGALLY & SOME DEFI NITIONS:
Under Section 279.04 or th e Crimin al Code of
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offe nce to ex pl o it a noth e r pe rson a nd by th e use of fo rce, decepti o n, o r
coe rc ion re move th e ir organs o r ti ssues - be it do m esti ca ll y o r inte m a tiona ll y.11 · 12 The re is however c urre ntl y no overa rc hin g fed e ra l law pro hibitin g C an adi a ns from o bta ining co mm e rc ia l o rgan tra nsp la nts overseas. whi c h we re so ld by a con se ns ua l do no r. 13 · 14 In 2009, th e Ho use of
Co mm o ns ne arl y passed Bill C -381 into law. 15 It so ug ht to ex pli c itl y
pro hibit Canadi a ns fro m go ing a broad to purc hase a n o rgan a nd wo uld
have crimin a li zed a ny so rt o f pa rti c ipa ti o n, eve n indirect, in o rgan traffi c king o r tra nspl a nt comm e rc ia li sm .
Bill C -3 8 1 wo uld have a lso required hea lth care pro fess io na ls to repo rt a n y pa ti e nts of the irs w ho had und e rgo ne tra ns pl a nt to uri s m , muc h
a kin to m andatory re po rting m echa ni sm s a lready in pl ace . 16 So m e acade mi cs a rg ue th at si mpl y ba nning thi s practi ce w ill no t wo rk .4 To co ntro l
a n indu stry tha t has bee n roug hl y estim a ted to gene ra te $600 milli o n to
$ 1. 2 billi o n a year-3 in profits w ill be diffi c ult, espec ia ll y w he n a m a rke t
of despe ra te ly ill a nd despe rate ly poo r peo pl e co ntinues to ex ist. T hey
co nte nd th a t o rga n scarc ity, w hi c h dri ves de m a nd .. need s to be dealt w ith
by in c reas ing o rgan d o na ti o n via po li c ies suc h as offe rin g in ce nti ve fo r
do na ti o n. Howeve r. it is ha rd to extrapo late th ese acade mi cs' a rg um e nts
furthe r, as it wo uld o th e rw ise lead to th e unjustifi a bl e posi ti o n o f a ll ow in g tra nspl a nt to uri sm in som e s ha pe o r fo m1 .

CONCLUS ION:
Fundam e nta ll y. th e iss ue o f o rga n trans pl a nta ti o n a nd comm e rc ia l ism is
o ne o f despe ra ti o n-dri ve n de m a nd . Phys ic ia ns sho uld e ns ure th a t th e ir
pa ti e nts unde rsta nd th e severe a nd f req uent s ide e ffects of tra nsp lant
to uri sm . Th ey sho uld ex pl a in the he in o us facts - the va ri o us c rimina l
o rgani zati o ns th a t th e tra ns pl a nt trad e fund s. a nd the in c redibl y une thical na ture of the trade, w hi c h is no thing sho rt o f th e ex pl o ita tio n of th e
poo r. T hese pe ril s mu st be communi cate d ea rl y. be fo re o rgan fa ilure, so
that pa ti e nts d o no t act o ut of despe ra ti o n . A nd if a pati e nt w ith a comm e rc ia l tra nspl a nt com es into th e ir care. they must s impl y re m e mbe r
th e ir duty to minimi ze th e pati e nt's s uffe ring a nd prov ide the best poss ibl e care for the m .
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T he sta k es a re no thin g m o re tha n th e li ves o f th e most v uln e ra bl e and
di stressed indi v idua ls in o ur communi ties a nd a ro und th e world.
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ABSTRACT
Lloyd Shapl ey and A lvin E. Roth have recently been awarded th e obe l
Prize in Econom ics for their work in match ing theory. A lthough branching from the field of economics. matching th eory has had many implications in the world of medicine. For exampl e. the Na ti onal Residency
Matching Program in the United States is an app licati on of matching
th eory. The focus of thi s artic le is th e applicati on of matching th eory
to kidney tran splant all ocation. Kidn ey tran splantation is th e best treatment fo r end stage renal fai lure. Unfortunately. th e demand for k idn ey
exceeds supply. Kidn ey paired exchange programs. which have begun
to gamer great success in increasing the number of kidney transpl ants
worl dwide. base thei r fo undations on matching th eory. Overviewed in
thi s paper wi l l be how these programs were created and work. their successes. and some of the unique challenges and logistical obstac les they
face.

I NTRODUCTION
Trad iti onally, markets functi on wi th monetary exchange faci litatin g th e
movement of goods to buyers from sellers. However in some instances
monetary exchange is unfeasibl e due to th e nature of th e market and as
a result. prototypical market structure is inapp licable. Matching theory
is a branch of game th eory that deals with thi s non-price allocation. Pi oneered by Ll oyd Shapley in the 1950s and 1960s, it has been appli ed
to real markets w ith great ucces . Two med ica l markets where matching theory has garnered thi success are re idency matching and kidney tran splant all ocati on whose designs owe greatl y to A lvin E. Roth .
an A meri can economi st who made great foray s into th e app licati on of
Shapl ey 's th eori es and their furt her development. Recent ly. both men
were award ed the Nobe l Pri ze in Economics fo r th eir work . In li ght of
its contem porary step back into the pub lic eye. thi arti cle wil l briefl y
outline matching th eory w ith some example from rea l markets. Finally,
th e application of matchin g th eory to kidney transplant all ocati on wil l be
ex pl ored, w ith a di scuss ion of its succe s and future direction s.

MATCH I NG THEORY: BA SICS
Shapl ey·s th eory is based on stable matching. In their 1962 paper. Gale
and Shapley demonstrated thi s idea w ith th e stab le marri age problem. 1
T he stab le marri age prob lem asked how a number of women could be
match ed to a number of men, con iderin g their respecti ve preferences to r
each member of th e opposite sex . They showed th at no matter th e preferences. th ere would alway s exist a stabl e all ocati on. A stable all ocati on is
one whereby no parties can be better off by further exchange. tabi I ity
is desirable in thi s exampl e and its rea l world ex trapo lati ons as stability
is seen as an indicati on of efficiency because furth er improvement of
happiness from exchange is impossib le. Addi ti onally, stability imparts
robustn ess to all ocation systems since it eliminates incenti ves for parti es
to disobey or manipul ate th e rul es of th e system. In the stable marri age
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prob lem. the soluti on was th e Gale-Shap ley .. deferred acceptance"' algorithm . Suppose the men are aii O\\ ed to propose to th e women. Each man
would propose to hi s favo urite woman. A woman w ith more th an one
proposa l would keep her favo urite proposal ·on hold ' without accepting.
and rejectin g all oth er . (Women wi th only one proposal would keep
that propo a! on hold as well. ) With th e second round of proposals. men
who were rej ected in th e preceding round would propose to their second
ranked woman. The women beha ve similarly as before. keeping their
best proposal on hold and rejecting the rest. including any proposals
from prev ious round s. Eventually. all women w ill have been proposed
to at which point they are all requ ired to accept their on hold proposals. It was shovm that all matches made in thi s manner were stable. A n
im pli ca ti on of the Gale-Shaple) algorithm was that th e propos ing party
wou ld secure more favourable matches.

MATCHING THEORY: APPLICATION
At the crux of thi s deferred acceptance algorithm is free trading. In th e
stable marri age problem. th e women were able to trad e tentati ve proposals fo r anything better th at came along. A lthough th e marri age problem
may seem con tri ved. it indeed has real world counterparts. One such
market is residency matching in the US. Roth demonstrated that the
matching algorithm used by the Nati onal Resident M atching Program
(N RMP) \\as able to make stab le matche becau se it was essentially an
ada ~ta ll o n o f th e Ga le-Shapl ey algorithm . 1 The allocati on of residency
positions was anoth er stab le marri age problem . w ith th e hospitals proposing to th e appli cants. Harkening back to th e stable marri age probl em.
Roth noted th at the algorithm produced outcomes favouring hospital s.
Moreover. With more physician coupl es w i hing to match to th e same areas. th e algorithm was proving insuffi cient in meeting th ese new needs.
In 1995 , Roth and Elli ot Peranson were enli sted to redesign th e NRMP
to accommodate coupl e matching. T heir algorithm was adopted in 1997
and used ever ince. 3

KIDNEY TRANSPLANT
T he best treatm ent lo r end stage renal failure is kidn ey transplant. Pati ents rece iving transplants li ve I 0 years longer than th ose 0 d. 1 · •
U r
I h
.
n 1a ysis.
n ortun ate y. t e demand for kidn eys outpaces the supply of deceased
donors With over 70% of Canad ians w ho are on organ waiting lists,
5
need mg a k i dney~ Livmg donors are another resource. prov iding > 16
yeats of dialysis-free survival compared to th e 8.6 years fronl a d
d
d
' u ·
ecease
onor.
ntortun atel y, th e challenge with utilizing thi s pool of li ving do~ors wa that many pairs of wi lling donors and recipients were deemed
mcompallbl e after. screenmg. In formation from th ese donor was usufor follow up and th e pair would be sen t home. 1 Wtth
·
ally not recorded
.
such congestiOn .on
donor waiting li st• th ere was an uroent
. th e. deceased
.
need to better uttltze lt vmg donors.
"'
A so lution to th e problem wou ld be another applicati on of Gale
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and Shapley 's matching th eory. Wh ereas th e marri age prob lem and th e
NRMP represented a two-sided mark et (two parti es matching with one
anoth er), th e kidn ey exchange problem is one-sided as every indi vidual
and their initial donor candidate is regarded as a sin gle item. Gale·s toptrading cyc le algorithm. whi ch also produces stabl e matches. wa the answer to thi s mod ifi ed allocati on problem. Objects are initi all y di stributed
to each entity and like the deferred acceptance algorithm . subsequent
trading occurs.' In kidn ey transpl antati on. th e initial all ocati on o f objects is analogous to th e pairs of incompatibl e donors and their intended
rec tpt ents. ow, imagine two incompatibl e pairs of a donor and rec ipi ent. I f each donor happened to be a match for the rec ipient in th e other
pair. a mutually beneficial exchange wo uld be poss ible w hereby both
patients receive a compatibl e donor. T hi s system of exchanges has been
dubbed Kidney Paired Exchange (K PE). Exchanges could and have become more com pi icated. with further pairs participating in a daisy chain
of trad es. KPE has also been adapted to make use of th e grow in g number
of altrui sti c or non-directed donors. 9 In domino-paired donati on, the altrui stic donor donates th e kidney to a recipient or an incompatibl e pair.
The donor of said pair wou ld th en donate th eir kidney to a compatibl e
rec ipient on the waitli st. Longer domino chain s have been accompli shed,
with the longest to date spanning 30 kidn eys and 60 indi viduals. 'u
SUCCESS
11

Si nce it was first suggested by Rapaport in 1986. several inform al exchanges have been reported . 12 Not until 2005 was the first nati onal KPE
program establi shed in the Netherl ands. 13 In the US. Roth helped design
th e New England Program for Kidney Exchange, 14 and along w ith th e
Ohio program was one of the early preludes to the national program
propo ed by UNOS in 20 10. In Canada. a three prov ince pilot program
initiated in 2009 and has become nationwide as of October 20 I 0. ,; Th e
Ameri can programs have seen increased numbers of kidn ey exchanges
in each subsequent year with > 1000 cumul ati ve transpl ants since 1998.
11
Researchers suggest that optim al utilizati on of th e program co uld see
as many as I 000-2000 additional tran splants per year in th e US; 16 aving th e country $750 milli on USD in dialys i costs annually. 17 With the
Canad ian program still in its infancy. th ere is insuffi cient data to evaluate its success. To date. the Canadian L iving Paired Donor Exchange
Registry has facilitated 144 tran splan ts w ith 14 more scheduled before
th e end of th e year. Increased tran spl ants mean more pati ents are experiencing a lessened burden of dialysis. better mortality. and a higher
quality of li fe. 'R

CHALLENGES AND FUTURE DIRECT IONS
KPE program impl ementati on elicits vari ous chall enges. One impli cation that arose was that all transplants wou ld have to be done simultaneousl y to prevent donor reneg ing. Only recentl y have non- imultaneous
donations been performed w ith altrui sti c donors bein g incorporated into
non-simultaneous extended altrui sti c donor (NEAD) chai ns. NEAD
resembles domino-paired exchange except th e last donor in th e chain
does not donate to a waiting li st recipient. but rath er becomes a bridge
donor. awaiting more pairs. Optimi sti cally, th e potenti al for ex tending
th e wave of exchanges outweighs the ri sk of donor ren eging. Some argue however, to not be overconfident because of th e honeymoon phase
where a single donor is abl e to initiate a large chain of donations. Many
chain s wi ll not propagate indefinitely and bridge donors accumulate as
matches become rarer. M any drop out after some peri od of tim e. 19 A
national KP E exchange also presents the need for co-ordination between
the variou s transplant centers and a centrali ze d registry. It is no surpri se
th at additional viable exchanges are easier to find with a larger pool
of pairs. However, there needs to be incentives for hospitals to enroll
donor-recipient pairs instead of performing short chain exchanges internally. As well , the tran sport of donors across th e country presents an-
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oth er chall enge both log isti ca ll y and fin ancially. T hese are all issues th at
need to be addressed i f KPE is to be used to its full potenti al.

CONCLUS ION
Thi s arti cle has prov ided an introd ucti on to matching th eory and th e
ways it has been applied in rea l markets. w ith special regard to kidn ey
transplant alloca ti on. The di scussion of KP E's permutat ions. successes and shortcomings here are definitely not ex hausti ve. For in stance.
th e ethical issues associated with KPE have not been add ressed here.
Further reading is encouraged for those interested. U ltim ately. matching th eory proves to be applicab le in many contex ts. and has especially
found some utility in th e fi eld of kidn ey transplantati on.
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Sun Country
HEALTH REGION

Rewa rding Physic ian
Job Opportunities
in South East
Saskatchewan.

Sun Country Health Region is currently recruiting for General Practice
Physicians, General Practice/Surgeon, and a Regional Locum. Each
opportunity has strong and established earnings potential and each
opportunity partners with other physicians . If you are eligible for
registration with the College of Physicians and Surgeons of
Saskatchewan we are interested in you!
Sun Country Health Region (SCHR) covers the southeast portion of
Saskatchewan Canada, from the Manitoba border to the U.S. border,
encompassing serene prairie and parkland . SCHR provides health care
services to the population of 54 ,000 residing in the region .

See www.suncountry.sk.ca for a
complete listing of physician job
opportunities.
Contact the Recruitment Team:
Phone: 306-842-8320
Toll Free: 1-866-578-7247
jobs@schr.sk.ca

-

.suncountry.sk.ca

Bluewater Health
Sarnia & Petrolia, Ontario
Bluewater Health is recruiting for the following positions to provide services to the residents of
Sarnia-Lambton both in the community and at the hospital.
•
•
•
•

Dermatologist
Paediatrician
Rheumatologist
Hospitalists

•
•
•
•

Neurologist
Psychiatrist
Emergency Physicians
Family Physicians (Petrolia)- including low acuity Emergency

Bluewater Health is a 320 bed hospital operating on 2 sites which includes a recently completed
$319 million redevelopment. The hospital offers excellent medical and diagnostic supports :
• A broad range of diagnostic services, including CT and MRI.
• Full spectrum of specialists available 24/7 (neurosurgery not available)
Sarnia was rated the Most Livable City in Ontario by the Pembina Institute (August 2007). Situated on the
shores of Lake Huron at the border to Michigan, Sarnia offers excellent quality
of life, sports, arts and culture, education , state of the art health care,
and beautiful natural environment
To inquire about these positions , please contact:
Dr. Mark Taylor, Chief of Professional Staff
Bluewater Health
Medica I_affairs@bluewaterhea lth .ca
519-464-4400 ext 4534 .
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The role of prostate-specific antigen (PSA) testing
in screening for prostate cancer
Charlotte Hunter (Meds 2015) and Paul Zamiara (Meds 2016)
Faculty Reviewer: Dr. D. Scott Ernst, MD, FRCPC (Department of Oncology, Division of Medical Oncology)

rostate spec ifi c ant igen (PSA) is a serin e protease ex pressed
mainly by th e prostate gland and detectab le in norm al, beni gn hy pertrophic. and neoplasti c prostate ti ue. Whi le th e majority of
the PSA produced by the prostate gland is released into emen, a small
amount (approximately one million-fold lower) norm ally leaks into th e
circul ati on and is detectable by immunoa a) . In the hyper- and neopl astic prostate, though. its secreti on into prostate ducts is lost and consequently more PSA is released into ex trace llul ar fluid and th e circul ati on.1
Serum PSA levels can therefore be used to track th e growth or shrinkage
of prostate tumors: indeed. th e FDA approved it u e to monitor cancer
progres ion (i.e. tumor grow th. response to treatm ent. recurrence) in already diagnosed men in 1986.1

P

PSA became th e first biomarker (indi ca tor of biological state) approved for screening asymptomati c men for cancer in 1994, when the
FDA approved its use in conjunction with the digital rectal exam (ORE)
to screen for prostate cancer. A PSA level of 4.0 ~ g/ L was traditionall y
con idered th e upper limit of norm al. and a prostate biopsy was recommended to patients exceed ing thi s level. However. prostate cancer
screening based on PSA level has limited specificity (33%. versus 86%
sensiti vity 3 ). as inflammation (prostatiti s) and benign growth (benign
prostati c hyperplasia) of th e prostate will also elevate PSA leve ls.2
Therefore, despite the PSA test ·s utility in monitoring tumor progre sion and response to treatm ent, its u e as a creen ing test for prostate
cancer in asymptomati c men remains controversial. Because of the con siderabl e publi c health burden imposed by prostate cancer - it was the
most diagnosed cancer in males in 2008 (about 899 000 cases and 258
000 deaths world w ide). w ith 72% of cases occurring in developed countries' - proper screening too ls and guidelines are ex tremely important.
The Canadian Cancer Society has suggested th at th e benefits of having a PSA test for screening purposes in clude the peace of mind granted
by a norm al result: identifi cation of those in need of further testing ( if
the result is higher than expected for th e pati ent" age): and the ability
to detect prostate cancer before it is symptomati c and/or before it has
spread beyond th e prostate.' However, th ey also point out th e potential
for harm as ociated with prostate cance r screening. such as the unnecessary anxiety cau ed by a fal se positi ve: the potenti al for a fal se negative
and th e propensity to then ignore worri some symptoms that may emerge
later: and th e ri sks associated with treatm ent of slow grow ing prostate
cancer that could have been left alone.
Th e current guidelines for prostate cancer screen ing in Ontario state
that PSA te tin g should not be used as a population-wide screen ing too l
for early detection of prostate cancer in asymptom ati c men.6 Instead,
physician should di scuss the benefits and potenti al harm s of testin g
w ith men who are between th e ages of 50 and 75 and have a life expectancy of at least I 0 years. Thi s di scu ss ion should also include men over
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40 w ith a first degree relati ve who has had prostate cancer. and men of
Afri can ancestry. With thi s inform ati on. men can th en decide for th em sel ve wheth er th ey would like to undergo testin g. A PSA va lue >4.0
~t g/ L or an abnorm al OR E \varrants furth er in vesti gati on.
Dr. George Kim (personal communi cati on. December 4. 20 12). a
famil y ph ys ician workin g in outh western Ontari o. restri cts hi s orderin g
of PSA tests to sy mptomati c men. In th e event of a 11 0rri some change in
prostate-related symptoms (i.e. increased urinal") urgency or freq uency.
or poor urinary stream 11 ith urinal")' trac t infection unlike!). e peciall y
when th e pati ent is of African descent or has a first degree relative diagnosed with prostate cancer prior to age 65 ). he prefers to send patients
for prostate ultrasound and possibl e biopsy. However. Dr. Kim find s the
PSA test to be a conveni ent test in th e interim i f th e ultrasound cannot
take pl ace within 10 days. In term s of screening. Dr. Kim be l ieves pati ents wo uld like to undergo a simp le test, like th e PSA test th at could
defi nitively detect cancer: because of thi s desire for certainty. patients
may have unreali sti c expectati ons regarding th e validity of test results.
He th erefore recommends di cu sing with pati ents th e advantages and
limitati ons of PSA testin g (including its low pecificity). and exp laining
why it cannot replace oth er surveill ance meth ods (i.e. th e ORE).
Tak ing a more ex treme stance th an th e Ontario gu idelines. the .S.
Preventi ve ervices Task Force recent!) recomm ended agai nst any
PSA-based screening for prostate cancer. regardl ess of age. based on
th eir conclusion th at many men are harm ed by thi s screening test and
few benefit from it 7 The Task Force· conclu ions were largely based
upon two ongo ing studi es: the U.S. Prostate. Lung. Co lorectal & Ovarian Cancer (PLCO) Screening Tria l and th e European Randomi zed tudy
of Screening for Prostate Cancer (ERSPC).
The PLCO tri al in vo lved 76 693 men bet11 een the ages of 55 and 74
who were randomi zed to annual P A screening for 6 year . co mbin ed
wi th a ORE for 4 yea rs. or care as usual.x A PSA va lue >4.0 ~g/ L was
used as th e cutoA· for a positi ve screen resu lt. The incidence of prostate
cancer was signifi cantly hi gher in th e screening group after 7 years of
fo ll ow-up (RR. 1.22 [95% C L 1. 16-1.29]). but th ere was no signifi cant
di lference in prostate cancer mortality (RR. 1.1 3 [95% C L 0. 75 -1. 70)) .
Th e I 0 yea r follow-up data. wh il e onl y 67% complete. was also con si tent w ith th ese findin gs.
The ERSPC trial rand omized 182.000 men bet11een the age of 50
and 74 to either th e screening group. w hich received a PSA te st ever)'
2-7 years (depend ing on the centre). or the control group, which received care as usual.'1 Most centres in th e tri al used a PSA cutoff value of
3 ~g/ L, with a positi ve screen result 1·\ arranting a biopsy. After a median
follow-up of 9 years. th ere was no stati sti ca lly significant difference in
pros tate cancer mortality bet11 een the men ass igned to th e screening
group and the controls ( RR. 0.85 [95% C L 0. 73~1.00]) . However. in ;

I Spring 2013

17

HEALTH PROMOTION
prespecifi ed subgroup of 162 243 men aged 55 to 69 there was a signifi cant abso lute ri sk redu ction in prostate cancer mortality for the men
ass igned to screening (RR. 0.80 [95% Cl, 0.65-0.98]).

REFE RENCES

Beyond the fact that th e resul ts of these t11 0 tri als do not prov ide u
with a consi tent answer to the questi on of whether PSA-based screening redu ces prostate cancer mortali ty, the U.S. Preventi ve Services Task
Force was som ewh at critical of the methods used in these trials. Both trials failed to exclude men who had had previou P A testin g, the PLCO
tri al had substantial contamin ation of the control group (up to 52% of
controls received a PSA test duri ng the trial). and the ERSPC trial used
a range of PSA cut-off points (>2.5 to 4 11g/ L) and screening intervals
depending on the centre."'

2. National Cancer Institute. Prostate-Specifi c Antigen (PSA) Test. Reviewed
Jul y 24, 201 2. http://'"' 11 ll .ca ncer.gov/cancenooics/fact sheet/detecti on/PSA
(Accessed on December I, 20 12).

The Task Force ·s dec ision-makin g was also influenced by harms associated with PSA -based creening. For exampl e. 75.9% of men who
underwe nt a bi opS) because of an elevated PSA va lue in the ERPSC
tri al had received fa l e-pos iti ve re ult .9 Complicati on of di agnosti c
eva luations occurred in 68 o f I0 000 procedures in the PLCO trial. and
in cluded bl eedin g. in fec tions. and urinary diffi cul ty'
Given the un certainty surrounding the interim res ults of these two
maj or tri als. it will be important to see whether longer-term foll owup of the study part icipants conveys a clearer message about whether
PSA-based screenin g red uce morta lity. Eve n with the current evidence,
the Task Force's strict recomm endation aga inst any PSA testin g for
creening purposes has been criticized for preventing patients from being in vo lved in decision-making." In a ew England Journal of Medicine commentary written in response to the Task Force's report, Drs.
McNaughton-Co llins and Barry (two prostate cancer speciali sts affi liated with Harvard Medi cal School and Massachusetts General Hospital)
argued for a strategy simil ar to Ontari o's guidelines in which patients
are made aware of the benefit s and harms assoc iated with PSA-based
screening and are able to dec ide for themselves whether the potenti all y
small benefit is worth it to th em. " However. they al so suggested that if
physicians continue to order PSA tests for screening purposes they must
do a better job of emphas izing the potenti al harm assoc iated with PSA
testing. rather than touting onl y the benefits of screening. Phys icians
must also make sure that th ey are not overtreatin g pati ents who might
benefit more from a "watchful wa iting" approach.
Thus fa r. measurement of abso lute PSA level for the purposes of
prostate cancer monitorin g and screening have been disc ussed. There
are other measurements to increase screening specifi city that are currentl y being ex pl ored. A recent retrospecti ve cohort stud y eva luated the
utility or a measure ca lled the PSA ve loc ity (P AV) ri sk count in 18 214
men enrolled in a prostate cancer screening study. 12 PSAV refers to the
yea rly change in PSA units, and th e ri sk count is a mea ure of the number of times PSAV exceeds 0.4 11 g/L. A PSAV ri sk count :::: 2 (i. e. two
consecuti ve yearl y increases in PSA leve ls exceedin g 0.4 11g/L) showed
96% specificity (compared to the reported 33% specifi city for the absolute PSA leveJ3) and was associated with a signifi cantl y in creased ri sk
of prostate cancer (O R 8.2 [95% Cl. 7.0-9.6]). In thi s stud y. the odds
ratio for prostate cancer determined by PSA level. in contrast. was onl y
1.25 (95% Cl. 1.22-1 .28). These results suggest that furth er in vesti gation or PSAV utility in prostate cancer screening is wa rranted.12 The US
Nati onal Cancer Institute al so li sts PSA density of the transition zone
(PSA le ve l di vided by the vo lume or the prostate 's transiti on zo ne) and
age-specifi c PSA reference ranges as parameters under in vesti ga ti on
for improve ment of PSA screening spec ificity.2 While these altern ati ve
screening opti on are being in vesti ga ted, Ontari o's recomm end ation that
patients hould be properl y informed about PSA testin g and encouraged
to participate in deci sion-makin g seems appropri ate.
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The living kidney donation process: role of the
interdisciplinary team
Yin Hui (Meds 2015) , Kyle Pangka (Meds 2016), and Alexander Yan (Meds 2015)
Faculty Reviewer: Dr. Faisal Rehman , MD, FRCPC , M.Ed (Department of Medicine, Division of Nephrology)

I NT ROD UCTION
End stage renal disease (ES RD ) is becoming an in creasingly preva lent
illness in Canada. 1 Th e Canadi an Organ Replacement Register A nnual
Report released by the Canadi an In stitut e for Hea lth In fo rm ati on (CIHI )
stated th at the number of Canadians I iving with ES RD has tripl ed from
1990 to 2009. 1 Unfortunately. the number of kidn eys donated has not
kept pace w ith thi s increase in demand . In 2009. appro ximately 38.000
Canadi ans are li ving with ES RD. with 59% on di aly is. and 3.000 pati ents on th e transplant wait li st. 1 Th e increase in di alysis trea tm ent also
comes w ith a ub tanti al cost to th e hea lth care system - th e estim ated
cost for hemodi alysis is $60.000 per pati ent. per year. 1 Th e C I HI estimates th at a renal transpl ant saves th e health care sy stem $250,000 per
pati ent over a fi ve-year peri od. 1
Due to th e shortage of cadaveri c kidn ey s. th ere has been an increase
in using donati ons fro m li ving donors. often from an offspring. parent,
or other geneti cally related family members. Donati ons from unrelated
donors also make up 30% of th e donati on poo l. with a porti on being
strangers to th e recipient. Several studi es have shown th at pati ents receivi ng li ving kidney donati ons from either geneti cally re lated and unrelated donors achieve better outcomes th an pati ents rece iving a kidn ey
transplant from cadaveri c donors.u; Livi ng-donor transplantati ons have
been shown to be assoc iated w ith a shorter time to transpl antati on, and
results in a better long-term graft and pati ent surv iva l 6 A s a result of the
in creasing importance o f li ving donati on, protocols have been deve loped to accommodate li ving donati ons: Li ve-Donor Paired Exchange,
L ive-Donor/Deceased-Donor Exchange. and A ltruisti c Li v ing ondirected Exchange.2 In th e Li ve-Donor Paired Exchange. a donor-reci pi ent
pair (th e pati ent req uiring a transpl ant, and a w illing donor who cannot
prov ide a matching kidney) is matched w ith anoth er donor-rec ipi ent pair
such th at a compatibl e donor-rec ipient exchange is made. Thi s matching proce ss, or chain , is continued until all rec ip ients receive a kidn ey.
In the Li ve-donor/ Deceased-donor exchange, a donor-rec ipi ent pair is
reassigned such that th e live-donor is matched w ith a rec ipient already
waiting on the deceased donor li st. In exchange, th e fi rst recipi ent is
moved nearer to th e top of th e cadaver li st. Finally. th e A ltrui sti c L iving
Nondirected Exchange is true to its name- th e kidn ey donati on comes
from a generous person who is a stranger to th e rec ipi ent.
To prov ide suffi cient care for both th e donor and recipient. a large
multidi sciplin ary team is required to address different facets of care, including processe of donati on. matching, and maintenance of care. Thi s
articl e will di scuss th e li ving kidney donati on process, as well as th e role
and importance of th e multidi sciplin ary team.

THE MATCHING PROCESS
Th e Li ving Donor Paired Exchan ge is a program run through the Canadi an Bl ood Services that identifi es matches betwee n potential li ving

UWOMJ 182:1

ki dney donors and transpl ant recipients in Canada.7 M atching refers to
th e tests carri ed out by clini cal scienti sts prior to transpl anta ti on to minimi ze th e ri sks of acute or delayed graft rejecti on. Thi s in vol ves ensuring the blood ty pe of th e donor and recipi ent are compatib le. testin g
th e hi stocompati bil ity of th e donor kidn ey. and screening th e pl asma
of th e rec ip ient fo r anti bodi es against donor ki dney cell s.8 To test fo r
hi stocompati bili ty th e surface molecules pre ent on th e donor and recip ient cell s. specifically hum an leukocyte antigen ( l-I LA) complexes.
are compared and assessed f or simil arity." Hi gher simil arity bet\veen
donor and recipient l-ILA complexes are associated with increased long
term surviva l rates. and a decreased chance that th e immune system of
th e recipient w ill identi fy th e donor cel ls as foreign." In dividuals may
have antibodi es against l-I LA complexes circul atin g in their blood due to
past transpl ants. pregnancies. or bl ood transfusions where th eir immune
system was exposed to foreign human cell s. 111 T hi s is w hy the pl asma of
recipi ents must be screened for antibodi es targeting donor ce ll s pri or to
transplantati on in a process kn own as cross matchin g. 1"

THE LI V ING KIDNEY DONATION PROCESS
In thi s secti on we wi ll focus on several components of th e organ donation process in cluding assessment of th e li ving donor. in fo rm ed consent.
and fo llow-up. T hese steps typically in vo lve th e presence of a transplant coordinator. physician. social worker. psychologist or psychi atri st.
and surgeon. Furthermore. throughout th e entire process th ere i usually a designated li ving-donor advocate who is ex peri enced in th e fie ld
o f transpl antati on. T he advocate can be a soc ial worker. coordinator.
psycholog ist. psychi atri st. or physician. Thi s advoca te shoul d advi se th e
donor independent fro m rec ipi ent interests.2

Assessment of the living donor
T he proces fo r determinin g donor accep tabi l ity may vary between
transplant programs. According to gui delines outlined by the Mu ltiOrgan Transpl ant Program of th e Uni versity Hea lth Network ( UI-IN) in
Toronto, separate hea lth care teams assess potential li vi ng donors and
rec ipi ents. Idea lly, thi s would include eac h donor and recipi ent w ith hi s/
her own physician. coordin ator. soc ial workers. and psychi atry staff.
Thi s is done to avo id potenti al conflict of interests. T he criteri a for assessment include low medica l/surgica l ri sk, ability to give inform ed
consent. realisti c ex pectati ons of donati on. vo luntary moti vati on. and
suffi ciency of economi c. practi ca l. and emoti onal re ources to cope w ith
th e donati on process. 17 The assessment process includes a ful l physical
eva luati on to ensure th at th e donor is hea lthy and th at th ere are no maj or
ri sk factors th at would lead to renal di sease in the future. Th e donor is
also evaluated for psychological and soc ial barri ers to donati on 2 T his
process requi res in vo lvement from all members of th e multidi sciplinary
team. Similar processes ex ist aero s Canada wi thin other multi -organ
transpl ant centres.
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In th e case of a di spute wi th in th e transplantati on team about th e suitabi l ity of a potenti al donor. th e team may rev iew the criteri a used to
measure suitability. A dditional sources of input may inc lude advi ce from
other pro fessional members of th e staff, ho pita! ethics serv ices. legal
coun el. hospital admini strati ve resources. or outside hospital consultati on.1 7

Informed consent
Inform ed con sent in vo l ves confirming th e pati ent's capacity to understand and consent. di sc losing inform ati on about th e proposed procedure. and ensuring vo luntarin ess. In th e contex t of organ donati on thi s
in vol ves a detailed discuss ion of th e ri sks and benefits to th e li v ing donor and rec ipient. T he potenti al donor sho uld be inform ed about altern ati ve treatm ent opti ons for th e recipient as we ll as th e poss ible impact o f
donati on on the donor 's lifesty le. famil y relati onships. fin ances. future
empl oyment. and abil ity to rece i ve li fe insurance. Donor and rec ipi ent
are ty pi call y prov ided w ith general info rm ati on and detail s on programspec i fi e outcomes. 17
Wh en a donor appears undecided. co un selling can be offered by a
social wo rker or psychiatri st to assist th e po tenti al donor to so lve problems and address psychosoc ial aspects of thi s dec ision such as emoti onal
issues and how to in fo rm others. Potenti al donors should be in form ed
that th ey can wi thdraw from th e process of donati on at any tim e w ith th e
full support of th e ITanspl antati on team. A cru c ial part o f th e assessment
proces is to ensure th at th e donor is makin g his or her dec ision free
from coerci ve or manipul ative intluences n

Follo111-up
It is important to evaluate donor and recipient exper iences in cluding
medica l. psychosocial and economi c outcom es. Accordin g to U HN
guidelines, early and late morbidi ty, graft functi on. mortali ty rates and
m easures o f recipient and donor sati sfac ti on are docum ented in an annual rev iew. In th e event th at a donor requires furth er ca re, appro pri ate
care is arranged. 17
T H E IMPORTANCE OF THE I NTERDI SC IPLI NA RY TEAM
As outl ined by th e prev ious sec ti on, th e interd isciplinary team plays a
cruc ial role in every step of the donation process. In additi on, th ere has
been a growing body of ev idence show ing th e benefit o f interdi sciplinary in vo l ve ment on quali ty of pati ent care (bo th donor and recipi ent).
pati ent sati facti on and surv iva l. In parti cular, a paper by Win sett and
Hath away identifi ed three areas of interventi on th at w ill increase the
pati ent 's quality o f life post-transpl ant: post-tran plant adverse events.
employm ent. and social support. 11 Literature has shown intcrdi ciplinary team s have been benefi cial for prov iding support fo r th e pati ent and
th eir family pre- and po !-transplant. A t th e Q ueen Eli zabeth II Hea lth
ciences Centre in Hali fax. it was shown th at a mu ltidisc ip linary k idn ey
di sease clinic co nsi ting of nephrologists, nur e educator and dietiti ans
was able to improve metabo lic and blood pressure co ntro l, and fac ilitate
th e use o f peritonea l d ialys is in late referrals for pati ents w ith chronic
kidn ey disease. 12 In a study by Fonouni , Go lriz, M ehrabi . et al. , an interdi sciplinary team con sistin g o f a transp lant surgeon, a nephro logi t, a
pediatri cian, a radi ologist, a psycho logist. a tran plant coo rdin ator. and
a transp lant nur e was shown to have improved staff communicati on.
pati ent outco mes and satisfac tion w ith th e hospital stay. 13 Several studies also showed an increase in favo urable mental and phy sica l outcomes
post-transpl ant w ith the in vo l ve ment of an in terdi sc ip linary team. 14·15-1"

C ONC L US ION
Th e increasing prevalence o f end stage renal di sease and th e shortage
of cadaveri c kidn eys underline th e growing importance o f li v ing kidn ey
donati on. However, li ving kidn ey donati on is a complex proce s th at
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merits carefu l ethi cal considerati on . T hi s process in vol ves co llaboration
between multiple health care professions on the side o f the don?r and the
recipi ent. Health care workers should ha ve an understa nding ot drfferent
aspects of support th at are in vo l ved in kidn ey donation in order to Illform others and alleviate anx i ety surround ing kidn ey donation . Several
studi es have already dem onstrated th at the current shift to w ard s a more
integrated and multidi sciplinary approach in kidney transp lantation improves pati ent care. sa ti sfacti on. and surv i val. Th erefore it should be
made clear th at the preparati on and ultim ate outcome of kidney tran splantati on does not depend solel y on the efforts of a nephrologi st or
transplant surgeon. but rath er a team effort.
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R

obotic surgery is a growing technology w ith th e potential to
revolutioni ze surgical procedures. especia lly in th e field of urology. Urology is at th e forefront of advances in thi s field. and
has integrated robotics into many procedures includin g rad ical cystectom ies. surgical nerve grafti ng and pyelop lasty. 1 Robo ti c surgery has
almost enti rely taken over rad ica l prostatectomy and th e role of robotics
is conti nuous ly expanding. Robotic surgery helps improve patient outcome b) minimizin g th e surgeon's movement tremors. increasin g range
of motion. decreasing blood loss. decreasing length of hospital stay. and
decreasing post-operati ve pain u Since the field of Urology deal s wi th
very difficu lt and delicate procedures. robotics offe rs an advantage by
allowing for greater accuracy. flexibi lity, smoother action s, and greate r
range of motion.
An important area of advancement for surgical roboti c is in the
field of imaging and vi sual feedback . Robotic surgery can be performed either with a surgeon con trolling the robot such as is done w ith
the da Vinci system to perform robotic-ass isted radical prostatectomies
(R'ARPs). or autonomou ly based on a predetermin ed algorithm such as
in th e case of rad iosurgery for pituitary adenomas.• While autonomous
robotic systems offer higher prec ision, and ti ssue-damage avoidance.
surgeon-controlled systems are much better at decision makin g in unstructured or chaoti c situations. For th e surgeon contro lling th e robot.
vi sual feedback can be attained using endoscop ic ca meras; however. for
au tonomous procedures. the con trol program req uires much more detail
about the patient 's anatomy.
General ly speaking. there are tw9 type s of imaging performed for
roboti c surgerie : pre-operati ve and intra-operati ve. Pre-operative imaging is acqu ired before a procedure and u ed for surgica l planning to
locate pathologies. a feed-forward system . In computer-guided systems
thi s can be prob lemat ic since th e images which are used fo r instrum ent
nav igation are based on ti ssue locati on at the tim e of imaging. However.
in strument deflection caused by instrum ent-ti ssue interac ti on as wel l as
ti ss ue movement can mean that the instrum ent positi on is not as preci se
as is desirab le. Thi s is especially problemati c when dealin g w ith small er
anatomi ca l targets. such as vascul ar surgery and in paediatrics.' Intraoperat ive imaging is used to provide close to rea l-tim e feed back. thereby
closing the feedback loop and all ow ing for adjustm ents throughout th e
proced ure. While tor surgeon control led roboti c , surgeons have th e
fl ex ibility of compensating via visual feed -back, for autonomous computer-controlled systems thi s cannot be as easily imp lemented due to th e
need for code to interpret th e vi ual feedback into a con trol for th e robot.

Resea rch into methods of providing a closed- loop feedback system
wh ich takes into account instrument deflection and ti ssue move ment
has been carri ed out u ing vari ou approaches. M eth ods of measuring
in strument position include computer vision techniques, 6 and electromagnetic sensor sy tems. 7 Thi s inform ation th en needs to be integrated
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into the computer control ystem to al lo w for changes in position as the
surgery progres es. Thi s has been achieved using Direct Image Guided
Interventi on (D IGI) robots. These robots use pre-operative images to
locate targets and create an initial nav igation protocol. They are also
connected to an im agi ng modality which all ows for real-time adjustments to thi s protocol. providing greater accuracy and prec ision than a
feed -fo rward system. Some challenges to DIGI include compatibility
bet\\ een robot and imaging modality such as MRI which has a dense
magnetic field. and most components of the robotic system cannot be
safe ly used in proximi ty to the magnet. Oth er problems include spatial
re so lution, and exposure to radiati on if fluoro copy or CT is used 8 The
Robarts Research Institute at Western Universi ty is investi gating the use
of two-dimen siona l transrec tal ultrasound (TRUS) to create three-dimensional real-time im ages by sweeping the probe about its axis. This
technology has been combined with surgeon operated roboti c surgery
for urologic procedures such as prostate brachytherapy or biopsy. 9
Another area of research wi th the potential to improve computer
ass isted surger) is haptics. Hapti cs is the general term used for touch
feedback. Thi s includes both tactil e feedback (i.e. temperature, vibrati on. tex ture. etc) and kinaesthetic feedback (i .e. force and position ).
The majority of th e work done regardi ng haptics in surgical roboti cs
is surrounding kin aesth etic feedback. rather th an tactile feedback. 10 A
known dra\\ back of robot ass isted minimally invasive surgery using
such surgica l robots is th e lack of haptic feedback . 11 • 13 This drawback
has been fou nd to be most limiting during compl ex tasks and can lead to
difficulty identifyi ng ti ssue ba ed on consi tency (i.e. between normal
and tum our ti ssue) and su ture breakage during knot ty ing. 14· "
The reason for th e lack or hapti c feedback in such system s is simple:
th e technology required is incredibly comp lex. The problem of providing hap ti c feedback can be broken down into two di stinct tasks: measuring the interact ion to rces and di splaying these to rces to the surgeon.
Measuring of interacti on forces during roboti c surgery has been attempted in a few different manners. Retrofi ttin g ex istin g surgical manipulators with commercially avail ab le force senso rs has been attempted; 19
however. constraints regarding size. geometry, biocompatibi li ty, steri lizab ility and cost have limited thi s approach. 11 ' Another method is to use
th e distance betwee n desired posit ion and actual position of the manipulator to determine force interactions between th e manipul ator and the
environment. Th is meth od has been imp lemented with some success;
however. it is limited by the non-ideal nature of the robot and the environment. meaning th at fri cti on and other dynami c forces are di fficult
to account lo r and can be large in comparison to the interaction fo rces
between th e manipu lator and th e pati ent. IO.lo
Methods of prov iding feedback to th e surgeon include direct force
feedback where motors in th e robot contro ls are programmed to recreate th e forces sensed by the manipu lator, and the use of other sensOJy
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feedback such as audio or visual feedback to represent th e forces ex peri ence d by the surg ica l in strum ent. Th e first meth od i th e mo t co mmonl y impl em ented meth od : 11 ' however. enabling a system to prov ide
force feedback in all directi ons actu ated by the system ( i.e. six degrees
o f freedo m plu s g ripping ) i not possible\\ ithout impl em enting a second
feedback system n U e o f motors to prov ide feedbac k also introdu ces
th e poss ibility o f feedback instability w hich ca n lead to uncontro lled
osc illati on . an o bv io usly undes irabl e event during surgery' " To get
around th ese pro bl em . va ri o u gro ups have attempted to impl ement
feedback system s using visual or aud io di spl a) s o f fo rce. 1 ~ - 13 - 1 ' T hese
system s have experi enced som e uccess and have potential fo r further
impl em entati o n as long as th ey do no t interfere with th e surgeon· v iew
of th e ti ssue thro ug h the v ideo displ ay o f th e endoscopi c cam era. 1"
Robotic surgery allo w s prec ise and repeated m oti ons w ith decreased
fa ti gue, m ooth er acti ons and increased accuracy. fl ex i bilit). and range
of moti on. especi ally in sm all confined anatomica l locati o ns such as th e
male pel v is during pro tate surgery. H owever, there are still limitati ons
in v isual and hapti c feedback . Th ese limitations. as we ll as training o f
surgeons. have stunted th e g ro wth o f thi s fi eld in om e ways: however.
as described. intensi ve re earch i s underway. It is c lear th at in certain
situati ons. it is be t to rely on image g uidance, allow ing th e surgeon to
be guided by more th an w hat is vi sible through th e vi sual fi eld . For
thi s to happen. imaging m odaliti es whi c h allow for greater compatibili ty
w ith th e surg ical robot w hile m aintaining as lo w radiati on dose to the
pati ent and surgeon as possibl e will need to be deve loped beyond th e
current techno logy. Similarl y. to ben er enabl e thi s ph ys ic ian to identify
spec ific ti ss ues. hapti c techno logy and its implementati on into surgery
w ill also need to be furthered . As th ese techno logies becom e increa ing ly incorporated in th e fi eld of surg ica l robotics. we can ex pect rapid
growth in th e number of surgeri es to m ak e th e transition from traditional
to roboti ca ll y -assisted or even full y autom ated.
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!epping into Dr. Faisal Rehman·s office. \\e could not help but
notice the count ies degree s. teaching award s. photographs and
thank-y ou notes th at decorated hi s wa ll s. On a Friday aftern oon.
we were luc!..··y to sit down and speak with the di stingui shed clini cian.
teacher and boxer at the Schu li ch School of Medicine & Dentistry.

S

A s the Nephrology Site Chief and the Director of Intern al Medicine
clerkship program at ni versity Hospital and chair of th e ge nitourinary block in the first-year curri cu lum . Dr. Rehman has a longstanding
history \~ith Western Uni versity. After completing a Bachelors degree
in pharm acology at the Univer ity of A lberta and a Medical degree at
Queen·s Uni versity. Dr. Rehman began his training in internal medicine at Schuli ch . He comp leted his nephrology fellowship in 200 1 and
wen t on to pursue a Masters of med ica l educati on at th e University of
Toronto. Dr. Rehman returned to Western Uni versity where he has since
establi shed a rewarding and successful academic medical career.
Dr. Rehman developed a fascinati on with medicine at a young age
under the influence of fa mil y and friend s in the profession . He set hi s
mind on internal medicine after expl oring clinical observerships but
admitted that choosing a specialty was a more difficu lt challenge th an
being accepted to medical schoo l. Dr. Rehman recognized near graduati on that intell ectually stimu lation through problem solving was what
he enjoyed most in med ici ne, leadi ng him to choo e a residency in internal medicine. Intern al med icine·s range combined with Dr. Rehm an·s
interest in longitud in al care ultim ate ly drew him to th e fi eld of nephrology. He loves nephro logy. he tell s us. because it involves comp licated
physiology, offers diversity - from transpl ants to glomerul ar nephritis to
diabetes- and all ows him to help patients in va riou s stage life: from
disease in the outpat ient clini c to dialysis, to transplan t, to tran splant
failure and return to dialysis.
When asked about th e future direction of research in hi s fi eld. Dr.
Rehm an says he see s portab le art ifi cial kidneys helping restore independence and improve quality of life fo r th e chronic hemodi alysis pat ients
he works closely with . l-Ie is hopefu l new kidney technology cou ld be
translated into clini cal practice since dialysis is an inconveni ence and
unpl easan t experience for patients. In addition. Dr. Rehman believes th at
th e delivery of care need s to be altered to accommodate th e in creasing
prevalence of chronic kidney di sea e. .. Unless we can have novel in venti ons like th e artifi cial kidney, I see our dia ly si populati on exp loding. I
see ou r CKD (chronic kidney di sease) cl inics being overw helmed. Unfortunately di sease prevention has not gotten a lot of hype."
A s for what he enjoys most abou t hi s career. Dr. Rehman 's respon se
was trongly echoed by the awards on his wa ll s: ·' t love to teach:· he
says. and especially being around students to teach them in the early
stages of th eir careers. In add ition to trad iti onal teaching in th e clas sroom. he has served as hon orary president of the Hippocrati c student

24

co unci l and oth er class co uncil s. Even his research interests complemen t
med ica l educati on. The projects he has overseen have included artificial
kidney modeling. training renal fellows and developing nephrology related research filters. In hi s words... the best reward is to see a student
mature and develop to the point they know more than you. And t·ve seen
th at in my students who are now consultants who have really excelled
in research or medical ed ucati on. It makes you proud that you have con tributed to that person developing.··
We could not leave Dr. Rehman's office without sati sfying our cu rio ity about hi s chari ty boxing career that lent him th e name King Faisal.
Outside of medicine. the physician indulges in boxing, which he enjoyed
watching as a child and training in as a youth. When the department
needed to raise money fo r kidney research 5 years ago, Dr. Rehman volunteered to rai se money fo r the Kidn ey Clini ca l Research Unit, thinkin g
at the tim e. .. I f t·m goi ng to do thi s. I w ill do my kind of event.'' With
th e help of a friend who was an internati onal boxing champion. the first
Knock Ou t Kidney Di sease annual gala was put together in a little over
a year in 2008. Not only did Dr. Rehman mastermind the organization
of the even t. he also trained to fight in the ring in order to rai se more
money. His initi ati ve and training paid off in a huge way : the event has
rai sed over $600 000 over th e past 4 years for th e Kidn ey Clinical Research nit and the Mathew Mailing Cen tre for Transitional Transplant
Studi es at Un iversity Hospital.
Dr. Rehman also shared with us one of hi s most memorab le pati ents,
w hi ch was an incredible case of hum an resilience. Thi s pati ent was Ms.
AL. a single moth er of five you ng children.\\ ho suffe red from sy stemic
lupus er) th ematous ( LE) and presented wi th severe skin rash. hematouri a. and proteinuria. Even though her kidney disease of membranou s
lupus nephritis was initial!) managed accordin gly w ith immunosuppressant • she started to develop severe hemoptysis secondary to lupus vascu liti s of th e lungs. She experienced further worsening of kidney functi on (acute kidney inju ry) and required multip le transfu sions of 20 to
30 units of blood. A ny further management of immunosuppression and
plasmophoresisju t seemed to make matters worse. She had a pro longed
hospital stay of 2 months, deve loped myocarditi s and lost a sionificant
amount of weight that severely lim ited her mobility. But just \~hen the
story could not get any worse. the pati ent sudden ly got better. She started to recover after Dr. Rehman stopped one o f her immunosuppressive
med rcatr ons. Now. she leads an active and fu ll li fe, does charity work
for a lupus society and is healthy enough to trave l all over th e world. Dr.
Rehman can only speculate that perh aps the powerfu l immunosuppressron meant to contro l her lupus had essentially functiona lly ablated her
bone marrow as a side effect. It was a memorabl e case for him because
she had been so close to death but then spontaneously got better with no
more signs of lupu . l-Ie says, ·'this case helped to reinforce that 1 need
to constantl y re-evaluate w hat I ' m doing, and to not stick to a recipe. It
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made me realize th at medicine is an art for some pati ents."'
For any medical stu dents considering the fie ld of intern al medi cine
and perh aps nephrology. Dr. Rehm an has some words of w isdom to offer. .. In my opin ion nephro logists are the classic interni sts. T hey have to
k n o\~ everyth ing about the body."' he says. A nephro logist is someone
who enjoys compl icated physio logy and longitudi na l care of pati ents.
eph ro logist work in a unique fie ld where pati ents can never be signed
off. T hey may need to be fo llowed from age I 0 to 12 years old until
death and everything in between: from dialysis. a transpl ant. back to
dialys i . and th ro ugh fami ly catastrophe. Lastl y. he tell s us th at. " th e
fi rst few year of medical school are not conducive to learning about
what you want to do when you grow up. What I found help ful is to really
max imize th e opportun ity to do observerships to get a fl avour of what's
invo lved to make a better decision. Tryi ng to narrow it down between
surgery and med icine up front may be help ful."
A lthough many clin icians lead rewardin g academi c medical careers.
few can claim th eir stud ents know th em as King Faisal. Dr. Rehm an
exemplifi es how extensive a phys ician's in vo lvement in medicine can
be. Hi s in vo lvement in pati ent care. medi ca l educati on. stud ent initi ati ves. research and fundraising all refl ect his di verse passions and speak
to hi s abili ty to maintain balance in his life and career. It is cl ear that Dr.
Rehman loves what he does and his pati ents and tudents clearl y appreciate all th e tim e he gives.
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Fever with incontinence in the elderly: an approach
for emergency medicine
Anthony Chow (Meds 2016) and Elaine Tang (Meds 2015)
Faculty Reviewer: Dr. Derrick Pringle, MD , FRCPC (Division of Emergency Medicine)

72-year-old man develops a high fever and is taken to the ER by
hi s conce rn ed w i fe and daughter. During th e intake interview.
he w i fe report th at th e man is experi encing worsening incontinence and occasionally complain s of dysuri a. Past medical record s indi cate th at th e man is alread) being treated and fo ll owed f or hypertension
and early A lzheimer · di sease. but th e wife notes th at it has become
increasingly di ffic ult to manage her husband 's confusion over the past
week.

k

duce a list of medi cati ons th e pati ent is takin g currently (ch lorthalidone
and rami pril for hypertension. galantamine for dementia, cyclazine for
nau ea. loratadine for seasonal al lergies) and confirm th at thi s degree of
confusion is hi ghly aty pical. Unexpected change in cognitive status is a
hall mark of pain in dementi a so I 000 mg acetaminophen is ordered.;
aft er establ ishi ng th at th e pati ent would have no kn own allergy or drug
interac ti ons. Vital signs are assessed and no abnorm al ities beyond high
blood pressure ( 145/90) and high oral temperature (40.5 °C) are found.

A n emergency physician receives th e above inform ati on from the
tri age nurse. Th e nurse adds th at th e man and hi s family have been 1\ ailing for two hours and all three appear qu ite distressed. How could such
a situation be managed?

SIGNS OF I NFECTION I N THE ELDERLY

GERIATRICS AN D DEMENT IA: CONSIDERATIONS FOR THE
BEDSIDE
The age of a patient carri es important implica ti ons for pati ent assessment and treatm ent. Th e phy siology of a hea lthy. older adult adapts to
functi oning w ith tissues th at have deteri orated with age. achi eving a
state of compromi sed balance term ed homeostenosis. ' Pati ents in thi
subpopulati on thu s have a reduced capacity to respond and adapt to th e
stresses brought on by ac ute illness and are more vulnerable to such
insults.
Thi s affects patient assessment. as it may be diffi cult to di stingui sh
symptoms of underl y ing disease from th ose of acute ill ness. Determining th e pati ent"s medical hi tory. current medi cati on regim e and soc ial
circum stances is also chall enging in an emergency scttin g 2 Prospecti ve
treatm ents are limited in th at th ey must not exacerbate or interact w ith
existin g conditi ons and treatm ents. Polypharm acy, in parti cul ar, di proporti onately affects th e elderl y and contributes to increased adverse drug
events. ph ysician visits, emergency admi ssions and hospital isati ons3
All th e above can be further comp li cated by dementi a in th e pati ent.
Th e pati ent's history may need to be obtained from fami ly members or
caregivers present in th e ER or staff at a care faci lity, potenti ally leading to mi stakes in interpreting symptom severity or mi sing incipi ent
problems entirely. Furtherm ore, th e pati ent may be unwilling or unable
to participate in diagnosti c or intervent ional measures th at become indicated through the co urse of care.'
Pain management is especially diffi cult and no less important for pati ents w ith dementia. Th ough not ideal. prim ary care physicians must
take care to detect surrogate mark ers of pain , uch as confusion. gesturing or posturing. through th e ph ysical examinati on.'
Returni ng to th e case, it is determ ined upon examin ati on that the pati ent does not have the capac ity to make hi s own medical dec isions when
he is unable to g ive hi s own name. Fortun ately, his wife and daughter
are attenti ve and meticulous prin cipal caregi vers. On request, they pro-
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Fever as a sign of in fecti on can operate quite differently in older adults.
Agei ng-m ediated impairment of th erm oregulati on means that fever can
fai I to occur in up to hal f of elderl y persons. despite the ex istence of I ifethreatening infecti on. Even norm al body temperature can be lower than
expected in th e elderly and even lower in th ose with dementi a due to the
same age-related changes.'·
G iven th e above. the fi nding of feve r in th e pati ent is a definite ca use
for conce rn . A n expl anati on for thi s sign is sought in th e next prominent
set of symptom : worsening incontinence and dysuria.

U RI NA RY I NCO TINENCE: DIFFERE NTIAL DIAGNOSIS
Age is the greatest determin ant of urinary incontinence ri sk . Many factors th at negati vely affect norm al micturi tion are more likely to occur
v. ith increasing age. With respect to transient incontinence. these include urinary trac t infec ti ons (UTl s). genitourinary muscle path ology,
acute i llncsses th at mandate immobi I isation or cath eteri sati on, fecal
impac ti on, medicati ons with autonomi c etTects or psychological expression o f dependency or rebelli on7
Th ough female are much more likely to experi ence incon tinence
th an males. several urologica l causes of in continence are exclusive to
male . For y ounger males. in parti cular, urethral and prostatic infecti on
seco ndary to a sex uall y-transmitled disease is a frequent cause of incontinence.' In older men, incontinence is more often related to prostate
disease. Prostate surgery is th e most common cause of stress urinary incontinen ce in men and prostate hypertrophy may cause overflow incontin ence by compressing the bladder.'' M ore importantly, UT! s are much
more comm on in older th an yo unger men, w ith an incidence approaching th at seen in women.'
In th e emergency departm ent, life-threatening causes such a cauda equina sy ndrome, spinal cord compress ion and paraspinal abscess
must additionally be rul ed out i f suspected. A bacteri al abscess cou ld
be consistent wi th typical infection-related observati on , li ke fever. and
can lead to both th e oth er conditi ons by direct or vascular compression.
A n MR I i necessary for rulin g out thi s po s ibility. ~<' I f additional lower
body motor or sensory symptoms are present, it is important to more
defini ti vely determin e wheth er th e cauda equ ina or spinal cord is af-
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fected.''
In th e present ca e. th e physica l examinati on is continued wi th an
awareness o f poss ibl e urologica l di sease. Palpati on of th e abdomen does
not reveal a di stended or swo ll en bladder. whi ch would have suggested
overfl ow incontinence.7
A s fever. dysuria and incontinence togeth er point convincingly toward a urologic prob lem. an abdomin al CT sca n is not indi cated at thi s
point. Instead. blood is drawn for routine chemi stry. A urethral cath eterisati on is perform ed to obtain a steril e urine sampl e for urinalys is and
urine culture. The pati ent is mildly uncooperative but accepting of oral
med icati on. so oral sedatives are adm inistered. ' 2 A bedside ultrasound
bladder scan is ordered to rul e out urinary retention and th e need to leave
the catheter in silu u
A n hour later. several r~po rt s are fonvarded fro m th e laboratory.
Blood urea nitrogen (BUN) and creatinin e are both normaL indicatin g
good kidney function. especia ll y for the patient's age.'• The routin e urinalysis report, on th e oth er hand. shows bacteria and l ~ uk ocy t e s in high
numbers in the urine (bacteriuria and pyuria) and th e nitrate test is positive. Thi s and urine turbi dity shift suspicion to urinary tract infection
(UTI) as opposed to th e more common urethriti s.' A nn ed with all of th e
above, the doctor return s to the bedside.

URINARY TRACT INFECTIONS: DIAGNOSIS
In th e elderly. investi gat ion for T i s needs to be justifi ed by a hi gh degree of suspicion because urinary incon tin ence and dysuri a alone are
very common and non-speci fi c. as di scus ed. In fact. conditions like pol laki uri a (frequent urinati on) and nocturi a (night urinati on) are estim ated
to be present in over 50% of individua ls over 60 years of age. 15 In thi s
population, even indi viduals w ith ou t infect ion often present 1vith th e
classic tri ad of UTI di agnosis: freq uency. urgency and dysuri a. 16
Diagnosis of UTI in an older adu lt. then. otien depends on nonurological indications. Th ese comm onl y in clude a general decrease in
day-to-day function. loss of v1eight or appetite. decreased alertn ess or
flank or abdominal tenderness. For patients w ith dementia. behavioural
deterioration and confusion can be extreme ly important symptoms. I('
For th e current patient. fever. confusion. dysuria and inco ntinence
create a strong suspicion of UTI, strengthened by th e subsequent findings of bacteriuria and pyuria. Upon further questioning. th e daughter
additionall y confinns th at lately the pati ent's appetite has decreased noticeably.

URINARY TRACT I NFECTIO S: MANAGEMENT IN THEELDERLY
Diagnosis and treatm ent ofUT i s in th e emergency department frequently
occurs without formal bacteria culturin g.' 7 Though it is possible for asymptomati c urologic bacteremi a to reso lve spontaneou sly in th e elderl y,
seri ous complications like renal damage. pyelonephriti s and sepsis may
occur, so it is prudent to treat all UT i s in th e elderly as complicated ."' 17
For most cases. a I 0- or 14-day course of the broad-spectrum antibiotic levo floxacin is indicated. Parti cul arl y for elderl y men. a fluoroquinolone like levo floxacin has the additional benefi t of high prostate gland
penetration. Recurrence and relapse are comm only seen in the elderly,
16
so proper follow-up must be arranged.
Returnin g to the case, th e pati ent is prescribed oral levo floxac in. 250
mg per day for 14 days and allowed to take acetaminophen as needed.
Given th e fever and neuro logical symptom s. however, the pati ent is con sidered at ri sk of developing sepsis. so it is decided w ith the wife and
daughter 's consent that it wou ld be most prudent to admit th e patient to
the medicine service.

T he next clay. th e patient's serum lactate remain s unremarkable and
repeat measurement of hi s vitals - particu larl y heart rate and 0 2 saturati on - return norm al findin gs. He is coo perative and much more aware
or hi s situati on. correctly provid ing hi s name. th e approximate date and
the fact th at he was in a hospital. " Sati sfied wi th the above improvem~nts . the phys ician di scharges the patient and asks th e wife and daughter to help fill and admini ster th e r~mainde r of th e prescripti on. T he) are
also instru cted to bring th e patient to ee hi s fami ly doctor in one week
to ensure clearance of the mi croorgani sm. confirm reli ef of neu rolog ica l symptoms and con sider management of incontin ence. i f it becomes
chronic. Refe rral to a urologi st is deemed unnecessary unl ess further
compli cat ion occ ur.
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Diagnosing in the dark: atypical proteinuria
etiology
Stephen Corn ish (Meds 20 15) and Eri c Roszell (Meds 2016)
Faculty Reviewer: Dr. Faisal Rehman , MD , FRCPC , M.Ed (Department of Medicine, Division of Nephrology)

zebra is a member of th e species of Afri can eq uids. of th e horse
family, whose appearance i defin ed by strikin g bl ack and 1vhite
tripes. These animals are rarely seen outside of th eir nati ve
continent. except for th eir requi site presence in zoos. menageri es. and
circuses. Wh en we think of someth ing th at is comm on. a zebra may
defi ne the direct antithes is to our noti on of commonality. L ikewise, a
zebra pati ent is, fo r a physician. a peculiar blend of an exciting presentati on and a fru strating di agnosis. T he helpful adage "comm on thin gs are
common" can be summarily thrown out of th e nearest w indow when
dealing w ith th e contents of th e Zebra Files.
Our case begin s wi th an 80 year old gentl eman presenting to hi s
primary care physician w ith an ac ute hi story of leg swelling and urinary frequency ove r the past three weeks. A n eva luati on of the present
compl aint determin ed th at he wa al o ex peri encing a reduced appetite.
nausea and vomiting. On examinati on. th e man ·s blood pressure was
138/78. and the lower ex tremi ties demonstrated th e fea tures of pitting
edema. ln ve Li gati ons were ordered. and return ed as foll ows: blood
urea nitrogen (BUN) of 7.3 mm oi/ L (norm al range 2.9 - 8.6 mm oi/ L).
serum creatinin e (Cr) of 45 7.6 umoi/L (norm al range 53 - 115 umoi/L).
and a serum album in leve l of 25 giL (norm al range 35 - 50 g/L ). Urinalysis was perform ed. whi ch detected th e presence of protein (graded
as a 3+ ) as well as gluco e in the urine. ~~ ith no remarkab le microscopi c
findin g .1 With these results and the clini ca l pi cture revea led. we can
begin to hypoth esize.
The finding of pitting edema on phy ical exam suggests an accumulati on of fluid in the interstitial space of body ti ssues. Fluid typica ll y
poo ls in dependent areas of the body like th e legs and feet. 2 T hi s is
refl ected in our pati ent, who had noticed an abnorm al swelling of hi s
lower limbs. Pitting edema i a ign of vo lume overl oad in pati ents.
which results in excess fluid eeping out of th e vascul ature into th e interstiti al space of body ti s ues. There are everal mechani sms by whi ch thi s
vo lum e overl oad phenomenon can occur. For th e ake of brev ity. heart
fai lure. li ver di seases such as cirrhosis. renal sodium retenti on. neph ro ti c
syndrome, drug-induced. and idiopathi c edema are all potential culprits.
espec ially in an indi vidual of advanced age.3 Differenti ating between
th ese etiol ogies is critical in ord er to proceed.
Building on our understanding of thi s pati ent 's volume statu s. we can
examine th e results of the initial in vesti gati ons. Both urea and creatinine
were found to be elevated, which indicate impairment of renal fun cti on.
The key to the pi cture here is th e urinalysis test. The significant presence of protein in the urine, classifi ed in this case as proteinuria of 3 out
of a poss ible 4 degree of severity, should not be seen in a healthy person
and is an indi cator of di sease.
A differenti al di agnosis for heavy proteinuri a would include glomerular causes such as glomerulon ephriti s, , diabetic glomeruloscle-

rosis. systemi c lupu erythematosus. amyloidosi s. and va culi tis. Other
causes may include. monoclonal proteinuria. multipl e myeloma. I) mphoma. or oth er neopl asia. 4 Renal fun cti on is dependent upon fi ltrati on in th e glomerul ar un it. resulting in th e remova l of 11as tes and th e
retention of bl ood ce ll s and protei ns. Fai lure to retain proteins sugge Is
damage to th e glomerulu. th e fi ltrati on unit of th e kidne) . The absence
of blood in the urine. or hematuri a. is also help fu l. Heavy proteinuri a
w ithout hematuri a fa ll into one category of renal di sease (nephrotic).
whil e th e combinati on is indica ti ve of a di fte rent type of path ology (nephritic) 5 T he measurement of a low albumin in th e in vesti gati on of thi
pati ent is refl ecti ve of th e heavy proteinuri a.
T he pati ent was referred by his primary care phys ician to a nephrology clinic for further evaluati on. Repeat urinalysis was perform ed . A
24 hour urine co ll ecti on for protein was perfonned. whi ch is more helpful for evaluatin g th e amount of proteinuria th an a di psti ck urinalys i
T he patient was losing 20 .7 g of protei n over a 24 hour period in hi
urine. Thi s more focused analysis returned anoth er curio us resul t: in addition to th e prev iously detected proteinuria. trace bl ood also appea red
in th e urine. Mi croscopic analys is identifi ed I 0-20 red blood cell s per
magnifi ca ti on fie ld, w ith some granu lar casts. 1 T he pati ent has now
demonstrated some degree of hematuri a observed in th e sett ing of heav)
proteinuri a.
T he findin g of hematuri a shifts the diagnosti c foc us away from a
nephroti c sy ndrome, which is categori cally limited to protein wastin g in
th e urine. and usually not blood. Glomerulonephriti s is an inflammatory
process defi ned by th e presence of red blood ce ll casts or d) smorphi c
red blood ce ll s in urine. moderate prote inuria hypertension. and renal
fa ilure.'' Ca uses of the nephriti c sy ndrome all relate to vari ous defecti ve
autoimmune proce ses: damage from th ese circ ulating factors occurs
progress ive ly as th ese factors accumul ate during glomeru lar fi ltrati on.
The underl y ing ca use of th e glomeru lonephriti s can be determin ed by
serologica l tests for th ese autoimmune facto rs.
aturall y. in our "Zebra" pati ent. th e usua l suspects in th e nephriti c
syndrome (anti-nuclear anti bod ies. A CA and anti-GBM antibodi es.
cryoglobulins. Hep C antibody. ASO titres) turned up negati ve. However. two protein s (C3 and C4) were fo und to be abnorm ally low.1 These
are norm ally in vo lved in th e compl ement cascade vital to the body's
immune respon e.
A renal biopsy was perform ed to determin e th e glomerul ar path ology. Light mi croscopi c eva luation showed classic charac teri stics of a
membranoproliferati ve glorn eru lonephriti . w ith form ati on of path ologica l crescents in 50% of glomeruli . A Congo red stai n was perform ed on
th e bi opsy ample: it return ed w ith a negati ve result. ruling out renal amy loido is. 1 A fter a circuitous di agnosti c route. th e elec tron microscop)
and immun oflu orescence on th e kidn ey bi opsy specimen did prov ide an
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ans" er. The architec ture of the glomeru lar basement membrane was being di srupted by randomly arranged fibri llary deposits. Final d iagnosis
was determined: fibril lary g lomerulon ephriti s with crescent form ati on.
in th e presence of hypocompl emen temia.
Fibrill ary g lomerul onephriti s is an uncomm on di ease of th e g lomeru lus leading to ren al dysfu nction .7 T his dys functi on is caused by a
buildup of randoml y arranged fibrillar deposit in th e glomerular base
m embrane and mesangium .8 The di ease was first distingu ished in 1977
from amy lo idosis on the basis th at co ngo red stains. which stain amy lo id
fibers. were negati ve in several patient" kidne) biopsies.' Fibri ll ary
g lomerul onephriti s has been associated with different malignancies,
m onoclonal gamm opathie s. and autoimmune di sorders.7 Despite th e
th oro ugh characteri zati on of fibri ll ary g lomerul onephriti s, the path o logy of th e disorder is not fully understood although it is kno11 n that th e
fibrillary depo its are derived from immunoglobulin .''
Cresce nts formation. as seen in our ··zebra·· pati ent. is seen in approx imate ly 20% of cases of fibrillary g lomeru lonephriti s. Crescent
result from a nonspecific respon se to severe injury of the glomerular
capill ary wa ll. These crescents can invo lve anyw here from 10% to 80%
of th e g lomeru lus. ' Since ere cents result from a nonspec ifi c re pon se.
th ey can be seen in any type of severe glomerul ar di sease.

PA : Saunders Elsevier. 324 p.
7. Ray S, Rouse K, Appis A. Novak R_ Haller NA. Fibrill ary glomerulonephriti s wi th hepatitis C viral infection and hypocomplementemia. Ren Fatl.
2008:30(7):759-762 .
8. Javaid MM. Denl ey H. Tagboto S. Fibri ll ary glomerulonephritis with small
fibril s in a patient with the antiphospholipid antibody syndrome success full y
treated with immunosuppressive therapy. BMC Nephrol. 2007 May:8( I ):7.
9. Schwartz MM . Korbel SM. Lew is EJ. lmmunotactoid glomerul opathy. JAm
Soc Nephrol. 2002 May: 13( 5): 1390- 1397.
I 0.

asr SH, Valeri AM , ornell LD, Fidler ME. Sethi S. Leung N. Fervenza FC.
Fibrillary glomerul onephriti s: a report of 66 cases from a single institution.
Clin JAm Soc Nephrology. 20 11 Apr;6(4):775- 784.

II . Collins M. Navaneeth an SD. Chung M, Sloand J, Goldman B. A ppel G.
Rovin BH . Rituximab treatment of fibrillary glomerulonephritis. Am J Kid
Dis. 2008 Dec:52(6) : 11 58- 11 62 .
12. Rosenstock JL. Markowitz OS. Valeri AM . Sacchi G. A ppel GB, D' Agati VD.
Fibri llary and immunotactoi d glomerul onephritis: distinct entitie wit h different clinical and pathologic features . Kidney Int. 2003 Apr:63(4 ): 1450- 1461.

A lthough fibri ll ary glomerul onephriti s is not generall y considered a
rare disease. as it is present in approx imately I % of kidney biopsies. th e
added com plicati on of hypoco mplementemia has onl y been reported on
one oth er occasion in the literature.7 H) pocomplentemia can refer to low
levels of the mo lecular mediators of compl ement: in our ··zebra·· pati ent
it refers to th e decreased amount of 3 and C4.
The treatment of fibri ll ary glomerulonephriti s w ith cresce nt form ation and hy pocompl ementemi a has not been we ll e tabli shed due to th e
rarity of th e condition . nfortunately. many of th e treatment option for
oth er ty pes of g lomerul onephriti s. such as teroid s or cytotox ic agents.
are ineffecti ve on fibrillary glomerul onephriti s7 Con er va tive use of
angiotensin inhibiti on is often used to contro l blood pressure and slow
th e progress of th e disease.' " Some o f th e th erapi es that have been attempted to ome uccess in vo lve th e use o f g lucoco rti co ids. predni sone,
cyto toxic agents such as cyc loph osphamide. and rituxi mab. 11
The prognosis for patients with fibri llary glomerul onephriti s is o ften
grave due to th e dearth of treatment opti on . The ex pected tim e co ur e
can be estim ated at th e tim e of a renal biopsy by different hi tologica l
features see n under li ght microsco py.12 Approximate ly 50% o f pati ent
w ill progress to end-stage renal di sease w ithin t'A o to six years. A mong
th e remaining patient . onl y 10% achieve co mplete or parti al remi ssion
w hile 40% have progressi ve renal di ease.'" With thi outl ook, our pati ent may have become one of th e grow ing numbers of pati ents w ho are
dependent on renal d ialys is th erapy. a d i fficult rea lity th at defines th e
medica l care of so many elder! ) pati ent .
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The barriers surrounding hemodialysis for patients
with ESRD: improving access since 1945
Justine Denomme (Meds 2015) and Wendy Cui (Meds 2016)
Faculty Reviewer: Dr. Shelley McKellar, PhD (Jason A. Hannah Chair in the History of Medicine)

emodi alys is is one option for renal rep lacement th erapy in people wi th End Stage Renal Di sease ( ES RD ). It is required when
a person· kidn eys are unabl e to comp lete th eir normal fu nction. th at of maintaining th e norm al intracell ular and ex tracell ul ar fluid
env ironment with in the body. 1 It en tail s remov ing excess fluid . as we ll
as waste such as urea. whil e rep lacing necessary substances such as
bicarbonate. 1 In thi s article. we present some of th e barriers surrounding
the implementation of di alysi for patients and ex plore how some of
th ese barriers were overcome.

H

EARLY DEVELO PME NT A D IMPLEMENTAT ION OF HEMODI ALYS IS
The first successful use o f hemodi alysis occurred in th e Netherlands in
1945 by Dr Will em J. Kolffwith a machine dubbed th e ·'artifi cial kidney.'"2 A 67-year-old woman suffer ing from acute kidney injury was
nearl y anuric. but wi th 11 .5 hour of dialysis. her blood urea nitrogen
and serum potassium levels dropped and she eventually made a full recovery. Di alysis. still experimental th en. wa re erved. as in thi s case.
for failures of conven ti onal treatm ent. 2 Interestingly. a Canadian surgeon, Dr. Gordon Murray, also invented a hemod ialysis machine around
the same time as Dr. Kolff3 In 1946, he successfull y di alyzed a woman
in a uremi c coma at Toronto General Hospital. Despite these succes es.
hemodialysis wa initially met with concern from physicians regarding
afety and efficacy. especi ally since treatment course was detennined
largely by tri al-and-error and few peop le were trained to operate th e
machineH However, throu ghout th e 1950 's. hemod ialysis gained populari ty and improvements and modificati ons were made to faci litate treatment and improve outcomes 5 It wa s indicated primaril y for pati ents
with acute kidney injury who on ly needed to be di alyzed temporari ly
rather than for ES RD as it wa difficult to maintain vascular access
for repeated di alysis to take place. 5 Thi s problem was reso lved in 1960
when Dr. Beld ing H. Scribner and co ll eagues introduced an arteriovenous shunt. which kept the rad ial artery and forearm vein in the arm of
the patient connected using Teflon tubing. 6 Thi hunt remained on th e
patient to maintain vascu lar access, faci litating connecti on with the hemodialyzer w henever dialy is was needed .6

O NCE HEMODIALYSIS BECAME AVAILABLE TO THOSE
WITH ESRD, WHO RECEIVED CA RE?
The Scribner shunt made hemodialysis a viable option for ESRD. In
1962. Dr. Scribner opened the world 's first outpatient dialys is centre
in Seattl e. 7 The Seattle Artific ial Kidn ey Centre consisted of on ly three
sets of dialys is eq uipment w ith limited staff. Thu , th e centre form ed
two committees to detennine wh ich patients were be t suited for hemodialysis. The first cons isted of nephrologi sts who ensured patients met
stringent medical criteri a. The second, the Admi ssion s and Policy Committee. consi sted of two phys icians, a Chri stian mini ster. lawyer, house-

w ife. businessman. and labour leader. It was also nicknamed ··the God
committee'" as its rol e was to asses the ·· relati ve worth .. of a candidate
to th eir fami ly and to soc iety at large and chose whi ch pati ents wo uld
survive and which would di e from th eir di seaseY Choices were al101\ ed to be gu ided by each member ·s conscience and pati ents cou ld be
eva luated on marital tatu s. occupati on. income. ed ucati on. emoti onal
stability. future potential. gender. and ageY Successful candidates were
usually th ose who were hard-working. had many chi ldren. were ac ti vely
in vo lved in church and communi ty affairs. but had few monetary sa vings such that i f th ey died. th e state would ha ve to support th e family.
As a result. th e decisions of th e Committee were large ly biased tO\\ ard
White. Protestant. middle-class m e n. ~ Committee members agonized
over th ese diffi cult decisions and criti cs fe lt that determining ··social
worth .. was unethical and sugge ted th at dec ision-making be based on
a method that does not penn it the compari son of socia l worth among
indi vidual s. such as choosing by lottery.7· 111 Fortun ately. such committees
became unnecessary a hemodialysis became more wid ely avai labl e. In
1972. U.S. Congress agreed to prov ide dialysis in end-stage renal disease for th ose who could not afford it. 9
The initial situati on in Canada is not unlike that in the United States.
Prior to th e implementati on o f th e 1966 Medical Care Act. regular dialysis trea tm ents were onl y offered in a fe\\ hospital due to prohibiti ve
costs.11 Again. th e question of who wou ld receive treatm ent and how
such al locat ions would be detennined posed a dilemma for physician s
and policy-m akers. Selec ti on com mittees regul ated who rece ived dialysis. based on criteria uch a age. th e stage of renal di sease. absence of
oth er comorbiditi es. and suitabili ty for kidney tran pl antation . It was the
death of a young man from kidn ey di sease in Montreal th at precipitated
th e creati on of th e charitabl e Kidn ey Foundation of anada in 1964.
dedica ted to advocacy. research. and support fo r Canadi ans w ith renal
disease. Eventua lly. under M edicare. th e cost of dia lys is was fully covered. all owi ng pati ents with renal di sease access to pre viously unattainable I i le-sav ing care. 11 Advocacy for hemodial ys is has saved many I ives.
In 2009. 22,3 I 0 Canadi ans \\ ith E RD were being treated w ith di aly sis.1 2A lthough it is known th at renal transp lantation is th e best treatment
for ES RD. the number of kidneys ava il able for transpl ant i not increasing as sharp ly as diagnoses of ES RD and demand for hemodialysis is
expected to increase in the future. 12

DEVE LOPME NT OF HOM E DI A LY S IS
Even with improved access, hemodia lysi , alth ough li fe- av ing. is very
tim e-consuming, invasive. and may negatively im pact qua lity of li fe. 13
One aspect of initial treatment wa that most patients needed to trave l to
a hospita l and dedicate everal hours a week to being di alyzed. A method
that circum vents thi s necessity. promoted in Canada by Dr. Robert U ldall and Dr. A ndreas Pierratos at the Uni versity of Toronto in 1993. is
home hemodialysis. Thi s method allow pati ents to perform dia lysis at
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home during sleep fo r most. i f not all. ni ghts o f the 11 eek." A lthough
pati ents mu st be trained. hom e dialys is has been associated w ith im proved quality of life and a higher cost uti l ity compared to traditional
in -ce nter hemodi alys is.' 5 Whil e home di alys is peaked in 1993 at 37.4%
of all d ial) sis in Canada. in 20 I I th at fi gure w as only 23 -2-1% in O ntari o.1 1 H om e dialy i can be di f fi cult to implement and unsuitab le for
some pati ents, but it o ffers an alternati ve fo r pati ents w ho wo uld prefer
to be trea ted at home.

I . Himmelfab J, Jkizler TA. Hemodialys is. N Eng! J M ed 201 0:363 : 1833 -4 5.
2. Gottschalk CW, Fellner SK. History of the science ofdi alys i . A m J Nephrol.
199 7 May-Aug; 17:289-298.
3. McKellar S. Gordon Murray and the artifi cial kidney in Canada. Nephrol Di al
Transpl ant. 1999: 14:2766-70.
4. BMJ Publishing Group. The artifi cial kidney. Br Med J. 1949 Oct
22 ;2( 4633 ):920-92 1.

5. A Iwall N. Hi tori ca l perspecti ve on the devel opment of the artifi cial kidney.
A rti fOrgans. 1986 Apr: l 0(2):86-99.

EXPANS ION OF DIALYS I S TO RURAL SITES
Canada is a vast co untry and many communities are isolated from large
hospital centres containing di al) sis units. Many pati ents are faced w ith
a shortage of dialys i stati ons i n th eir area and have a limited abilit) to
se lect th eir pref erred locati on or chedul e for di aly sis. Pati ents li v ing in
rural areas may need to make hours-l ong dri ves to th e nearest hospit al.
a heavy burde n in vu lnerabl e popul ati on uch as th e elderl y and d isabl ed.'6 A del ivery model proven to be safe and effecti ve in Ontari o is
the satell i te mode l. in w hi ch rural satellite sites are paired w ith a larger
centre or ··hub.. to ensure th at w hil e pati ents may recei ve hem odi alys is
in a rural sett ing. the) are still granted access to an experienced nephro logy team. 17 A n example of a sa tellite di alys is unit ca n be fo und in Goderi ch. O ntari o. a town of 8, 000 residents abo ut an hour north of L ondon,
O ntari o. Opening in 200 I as a atellite of th e L ondon Hea lth Science
Centre Renal Program. th e fac ility can accomm odate 12 pati ent per
day w ho wo uld oth erw ise need to travel to L ondon for hemodi alys is."
A nephrologi t from L ondon v i its approx im ately once a month for pati ent assessment and adj ustm ent of medi cati ons and co nference ca lls are
made to discu s pati ent ca re on a 1\ eekl y basis. A lthough such fac ilit ie
are prim aril y for the m ost stabl e pati ents requiring d ialys is. th ey have
empowered small er co mmuniti es and helped alleviate some of th e added
di ffic ulties of havi ng ES RD in a rural settin g."

6. Quinton W. Dillard D. Scribner BH. Cannul ati on of bl ood vesse ls for prolonged hemodialys is. Trans Am Soc A rtif Intern Organs. 1960 A pr 1011 ;6: 104- 13.
7. Blagg CR. Development of ethi cal conce pts in dialys is: Seattl e in the 1960s.
Neprhology 1998 A ug:4 :235 -38.
8. Jonsen AR . The god squad and the origins of transpl antation ethi cs and policy. J Law Med Ethi cs. 2007;35(2):238-40.
9. McGough LJ , Reynolds SJ, Quinn TC, Ze nilman JM . Whi ch patients first?
Setting pri oriti es for antiretroviraltherapy where resources are limited. A m J
Public Health. 2005 Jul ;95(7): 11 73 -80.
I 0. Sanders D. Dukeminier J Jr. Medical advan ce and legal lag: hemodialys is and
kidne} transplantation. UCLA Law Rev iew. 1968 Feb: 15(2):357-41 3.
II. K idney Foundation of Canada. (20 12). Vision and M iss ion. Retrieved from
http://www.kidney.calpage.aspx? pid=305
12. Canadian Institute for Health Jnforn1 ation (C IHI ), Canadian Organ Replacement Register Annual Report : Treatment of End-S tage Organ Failure in Canada. 2000 to 2009 (Ottawa. Ont. : Cl HI. 20 II ).
13. K immel PL. Just whose quali ty of life is it anyway? Controversies and consistencies in measurements of quali ty of li fe . Ki dney Int. 2000;57 :S 11 3-S 120.
14. Pierratos A . Noctumal home haemodialysis: an update on a 5-year experience. ephrol Dial Tran splant. 1999 Dec: 14( 12):2835 -40.

CONCL SIONS
Access to hemod ialys is has improved ove r th e yea rs and pati ents are
now empowered w ith more opti ons for treatm ent. inc luding home dialys is and access to atellite si tes. However. accessi bility to trea tm ent
remain s an iss ue fo r chronic ki dney di ease and ES RD pati ents. A s th e
prevalence o f k idney disease ha increased. so has demand for dialys is.
from more th an 5 900 Canadi ans on di alys is in 1990 to 22 300 in 2009.
an increa e from 53% to 59% of all ES RD pati ents. 11 Furtherm ore, for
m any pati ents, transpl antati on remains th e ultimate goa l o f treatm ent. It
is known th at renal transpl antation is &enerall y more effecti ve at treatin g
pati ents w ith ES RD and th ose transpl anted report a g reater qualit) o f
li fe.' " In addition. th ee tim ated cost for hem odialys is is approx imately
$60 000 per year of treatm ent, per pati ent, w hil e th e cost for a one-tim e
kidney transpl ant. inc luding annual maintenance medicati on. is $29 000.
T he sav ings are $2 50 000 over a fi ve year peri od, especiall y relevant in
I ight of many recent cuts to hea lthca re in O ntari o.' 1
Du e to limited acce s to donor organ . guidelines have been deve loped to determin e w hi ch pati ents are eli gi bl e for kidn ey transpl antati on, hearkening back to th e earl y days of hemodialys is. A s bi oethi cs
has evol ved from dark er days in Sea ttl e, th ese criteri a are much more
transparent and ev idence-ba ed. ontroversies in organ donati on remain. such as w hether pati ents o f ad va nced age or cogniti ve impairment
are treated fa irl y w ith i n th e sy tem.211 By advoca tin g for pati ents to sign
donor cards and ex press th eir w ishes to famil y and fri ends, ensuring th at
all pati ents w ho may benefi t from transpl antati on are as e se d and added
to wa iting lists. we ca n pl ay a ro le in ensuring th at acce s to hemodi aly sis rem ain w ide pread, and open to newly di agnosed pati ents and th o e
in elig ible for transpl ant.
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